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INTRODUCTION 
 
 Systemic lupus erythematosus (SLE) is an autoimmune disease with 
multiorgan involvement. The skin is the second most commonly affected organ. 
SLE with skin lesions can produce considerable morbidity resulting from painful 
skin lesions, alopecia, disfigurement, etc. Skin lesions in patients with lupus may 
be specific (LE specific) or may be non specific (LE non specific). Acute 
cutaneous LE (Lupus specific) has a strong association with systemic disease and 
non-specific skin lesions always indicate disease activity. Therefore, a thorough 
understanding of the cutaneous manifestations of SLE is essential for most 
efficient management.  
 
 The spectrum of disease ranges from minor organ involvement (e.g., 
cutaneous lesions) to life-threatening major organ involvement (e.g., renal, 
nervous system, etc.). 
 
Skin is the second most commonly affected organ after joint involvement 
and skin lesions are the second most frequent way that this disease presents itself. 
Skin and mucous membrane are symptomatically involved at some point in over 
80% of patients with SLE. Skin lesions in these patients produce considerable 
morbidity by producing alopecia, scarring lesions, disfigurement, etc. and for 
these reasons about 45% of patients experience some degree of vocational 
handicap. 
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 There is great variation in incidence, clinical heterogenecity, and severity 
of disease between different ethnic and racial groups due to environmental, 
cultural, and genetic variability. Diversity was also noted in the type of skin 
involvement ranging from classical butterfly rash, discoid lupus to bullae, 
alopecia, vasculitic rashes, etc. 
 
 Cutaneous lesions are important as a diagnostic aid as these account for 4 
out of 11 revised ARA criteria for disease classification. Moreover, lupus-specific 
skin lesions serve primarily as an important diagnostic clue whereas lupus non-
specific skin lesions are associated with more active disease and thus require 
more aggressive therapy and disease monitoring. Thus, a thorough understanding 
of cutaneous lesions in SLE is critical for efficient diagnosis and management 
 
  
Review of literature 
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REVIEW OF LITERATURE 
 
 Lupus erythematosus (LE) is a group of  heterogeneous illnesses due to the 
development of auto immunity to self-nucleic acids and associated proteins. 
 
 Its clinical spectrum ranges from mild skin involvement  at one end to the 
risk fatality from the systemic manifestations of LE such as nephritis, central 
nervous system disease, or vasculitis1 . 
 
HISTORY  
 The disease is said to have been coined as lupus in the 13th century, 
because it ate away parts with the rapidity of a wolf2. 
 
 Knowledge regarding the involvement of blood vessels, viscera, connective 
tissue gave the concept of “multisystem malady”2. Similarities among the diseases 
such as Dermatomyositis, Rheumatoid Arthritis, Scleroderma, Polyarteritis 
nodosa led to the classification of these diseases under the umbrella term of 
“collagen disease” or “collagenosis” . 
 
 The discovery of autoantibodies in the last few decades has led to the 
present concept of “AUTOIMMUNE DISEASES”3. 
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 Lupus erythematosus (LE) is characterized by the development of 
autoimmunity  predominantly at the molecular constituents of nucleosomes and 
ribonucleoproteins.  
 
 Some patients present with life-threatening manifestations of systemic LE 
(SLE); whereas others, may express only discoid LE (DLE) skin lesions 
throughout their illness.  
 
 The pattern of skin involvement expressed by an individual patient with LE 
can provide insight about the position on the spectrum where the patient’s illness 
might best be placed3. 
 
GILLIAMS CLASSIFICATION5 
James N. Gilliam originally  divided the cutaneous manifestations of LE into  
1. LE-specific skin disease: those lesions that show characteristic 
histologic changes of LE and  
2. LE-nonspecific skin disease: those that are not histopathologically 
distinct for LE and/or may be seen as a feature of another disease 
process. 
 
 The term “LE-specific” relates to those lesions displaying  interface dermatitis.    
  
5 
 
 
 
CUTANEOUS LUPUS ERYTHEMATOSUS 
 Cutaneous LE (CLE) is often used synonymously with “LE-specific skin 
disease” as an umbrella designation for the three major categories of LE-specific 
skin disease5: 
 
1.  acute cutaneous LE (ACLE) 
2. subacute cutaneous LE (SCLE)  
3. chronic cutaneous LE (CCLE) 
Systemic lupus erythematosus 
SLE is a multisystem disease most commonly  involving  
1. Skin 
2. Joints 
3. Vasculature 
with associated immunological abnormalities. 
 
CRITERIA 
 ARA, American College of Rheumatology  in 1971 developed the first 
criteria for classification. It was modified in 19821.  
 
 The Systemic Lupus International Collaborating Clinics (SLICC) 
developed  17 criteria with higher sensitivity but lower specificity for the 
diagnosis in  2012. 
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Systemic Lupus International Collaborating Clinics classification criteria for 
(SLE), 20124. 
 
Clinical criteria Definition 
1.Acute cutaneous lupus  
 lupus malar rash, bullous lupus, toxic epidermal necrolysis variant of SLE, 
maculopapular rash, photosensitive lupus rash in the absence of dermatomyositis; 
or subacute cutaneous lupus SCLE 
2.Chronic cutaneous lupus 
Classic discoid rash DLE, hypertrophic(verrucous) lupus, lupus panniculitis 
(profundus), mucosal lupus, lupus erythematosus tumidus, chilblain lupus, discoid 
lupus/lichen planus overlap 
3. Oral ulcers: palate, buccal, tongue or nasal ulcers in the absence of other 
causes 
4. Non‐scarring alopecia: diffuse thinning or hair fragility with broken hairs 
excluding other causes 
5. Synovitis: involving two or more joints with effusion or swelling or tenderness  
and at least 30 min of morning stiffness 
6. Serositis: pleurisy or pericarditis, for more that 1‐day duration of 
pleural/pericardial effusions or pleural/pericardial rub 
7. Renal disorder:  persistent proteinuria (>0.5 μg/day) or cellular casts 
8. Neurological disorder:  seizures, psychosis, mononeuritis multiplex, myelitis 
or acute confusional state in the absence of other causes 
9. Hemolytic anemia 
10. Leukopenia (<4000/mm3 at least one occasion) or lymphopenia 
(<1000/mm3 ) 
11. Thrombocytopenia (<100 000/mm3 at least once) 
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Immunological criteria 
1. ANA above reference laboratory range 
2. Anti‐dsDNA antibody above reference laboratory range (or more than 
twofold 
3. the reference range if tested by ELISA) 
4. Anti‐Sm: presence of antibody to Sm nuclear antigen 
5. Antiphospholipid antibody positivity 
6. Low complement (low C3, C4 or CH50) 
7. Direct Coombs’ test in the absence of haemolytic anaemia 
 
Criteria need not be present concurrently. 
 
A patient must satisfy at least four criteria, including 
1. One clinical criterion  
2. One immunological criterion 
  or 
 The patient must have biopsy‐proven lupus nephritis in the presence of 
 ANAs or anti‐double‐stranded DNA (anti‐dsDNA) antibodies. 
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EPIDEMIOLOGY 
 SLE is a relatively uncommon inflammatory disorder. Prevalence of SLE 
in India is estimated to be 30 per million people. SLE is a frequently overlooked 
disease due to lack of awareness. The average diagnostic delay is almost 4 years. 
On the other hand, SLE is often over diagnosed on the basis of positive laboratory 
results in absence of appropriate clinical features. A study reported in rural 
northern India showed the prevalence to be 14 to 60 per 100,0006. 
 
SEX AND AGE 
 Females are affected more frequently (7 : 1 and 15 : 1)  than males10 9. The 
condition tends to occur in early adult life, and the peak age of onset of the first 
symptom or sign in females is approximately 38 years, younger onset is noticed in 
Indian population; it is 44.2years in men6 .  
 
 The manifestations of the disease are the same in all age ranges, although 
serositis and Sjögren syndrome are more common disease manifestations in the 
elderly 7. Men with lupus tend to have higher frequencies of renal disease, skin 
manifestations, cytopenias, serositis, neurological involvement, thrombosis and 
vasculitis.  
 
AETIOLOGY 
GENETICS: Genetic factors play a considerable role in the pathogenesis of 
SLE8. It has been reported in identical twins, with a concordance rate of 65%9. 
However, most individuals with SLE have no family history of the disease. 
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COMPLEMENT  
 Rare mutations resulting in deficiencies of the classic complement system 
or defective degradation of DNA commonly result in the development of SLE.  
C1q DEFICIENCY result in SLE‐like disease in 93% of individuals. C1R/C1S 
deficiency or CD4 deficiency and up to 25% of C2‐deficient individuals develop 
SLE 11. 
 
TREX1 
 Mutations in TREX1 (three prime repair exonuclease 1), a gene encoding 
an intracellular nuclease,  are also found in up to 2.7% of patients with SLE and 
are associated with neurological impairments 10. 
 
HLA 
Over 35 genetic loci, replicated in more than one study, have been identified with 
most disease‐specific genes grouped into four immunological pathways: 
1.  innate immune response 
2.  immune complex clearance 
3.  adaptive immune response  
4. epigenetic modification 
 
 Class II HLA molecules are important for the presentation of antigen to 
CD4 T cells and the promotion of T‐cell‐dependent antibody responses. The most 
consistent associations are between HLA‐DR2 and HLA‐DR312. 
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AUTOANTIBODIES 
 A range of autoantibodies may be present in the disease,  
1. some are more disease‐specific (anti‐dsDNA and anti‐Sm antibodies) 
2. some are more common (antinuclear and anti‐Ro antibodies).  
 
 Autoantibodies found in SLE are either germ‐line encoded or the product 
of somatic hypermutation. 
 
BAFF  
 Elevated levels of B‐lymphocyte stimulator (BLys; also known as B‐cell‐
activating factor (BAFF)), a growth factor that is particularly important for the 
survival of T‐cell‐dependent B cells that promote, B cell formation and thus 
autoantibody formation13.  
 
 Belimumab, a monoclonal antibody to BAFF, improves mucocutaneous 
and arthritis symptoms in patients with SLE in clinical trials. This drug has 
become the first US Food and Drug Administration (FDA) approved therapy for 
SLE. 
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AUTOANTIBODY 
 
ANTIGEN- ANTIBODY COMPLEXES 
 
TLR 9, TLR 7 
 
ACTIVATION OF INNATE IMMUNITY 
 
IFN‐α , TNF‐α RELEASE BY DC 
 
IFN‐γ, IL‐6,  IL‐10 BY T CELLS 
 
MORE ANTIBODIES 
 
 
 In SLE, antigen–antibody complexes activate the innate immune system 
through the stimulation of Toll‐like receptors (TLRs) 9 and 7. Innate immune 
activation leads to INF‐α and TNF‐α release by dendritic cells and this release 
promotes T cells to release IFN‐γ, interleukin 6 (IL‐6) and IL‐10 which are all 
cytokines that promote continued antibody formation. The autoantibody‐
producing cells are inadequately down‐regulated by anti‐idiotypic antibodies and 
regulatory T cells14.  
 
Anti‐Ro Neonatal LE 
Antiphospholipid antibodies  
( lupus anticoagulant) 
Thrombosis and abortion in patients with 
SLE 
 Antiribosomal P proteins Lupus Psychosis 
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AUTOREACTIVE T AND B CELLS 
 SLE causes dysregulated production of type 1 IFNs, principally INF‐α. 
This results in the dendritic cell activation of autoreactive B and T cells. IFN‐α 
dysregulation also results in activation of the innate immune system and vascular 
disease, common in SLE. 
 
 There is an increase in memory B cells and circulating plasma cells whose 
numbers correlate with disease activity15. 
 
 There are deficiencies in the function of regulatory T‐cell subsets . 
Cytolytic CD8+ T cells sustain rather than suppress B‐cell responses and 
lymphocyte transformation responses to common antigen.  
 
 The role of IL‐2 as a primary activator of regulatory T cells rather than 
general T‐cell growth factor is being considered now. In SLE, the production of 
IL‐2 by peripheral blood leukocytes is impaired, thus reducing the inhibitory 
effects of regulatory T cells upon activated B cells, and the increased longevity of 
autoreactive T cells16. 
 
ENVIRONMENTAL FACTORS 
Environmental factors associated with the onset of SLE include  
 exposure to sunlight and UV radiation 
 smoking 
 infections 
 stress 
13 
 
 
 hormonal factors  
 medications such as TNF inhibitors, silica and solvents. 
 
 SUN and UVR: UV radiation may precipitate the onset or exacerbate the 
course of SLE in up to 60% of patients. Clinical photosensitivity in the form of 
polymorphous light reaction and pruritus is associated with more severe systemic 
disease.  UV‐mediated oxidative DNA damage has been shown to induce 
resistance to 3´ repair exonuclease 1‐mediated degradation, resulting in increased 
local type 1 IFN production which eventually leads to autoimmunity17. 
 
 Studies in children suggest that  Epstein–Barr virus infection may be a 
trigger initiating SLE 18.  
 
HORMONES 
 Oestradiol, prolactin, testosterone and prolactin are thought to modulate the 
incidence and activity of SLE. Oestrogen containing contraceptive compounds, 
early menarche and postmenopausal oestrogen use all increase the risk of SLE19. 
Men with Kleinfelter syndrome have a higher incidence of SLE, possibly related 
to hormonal factors. Prolactin is an immunoregulator and enhances B‐cell 
proliferative responses to antigens. Prolactin levels are increased in patients with 
SLE and gonadotropin‐releasing hormone (GnRH) is secreted by 
immunologically active cells, further elevating prolactin levels and suggesting an 
autocrine effect20. 
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DRUGS 
 SLE precipitation by drugs, especially the antihypertensive hydralazine is 
common. 
 It occurs in older age group.  
 The renal and central nervous system involvement is infrequent 
 Antihistone antibodies are frequent, anti‐DNA antibodies are absent and 
serum complement is normal21.  
 
 Hydralazine is known to inhibit binding of complement component C4, 
and this action,  may explain the development of lupus like syndromes.22 
 
 Procainamide and hydralazine are potent DNA methylation inhibitors 
which eventually result in the increased activation of autoreactive T cells. It has 
been proposed that drug‐mediated alterations in DNA methylation may underlie 
the initiation of most forms of drug‐induced SLE23. 
 
 Minocycline‐induced carries a definite associated risk, though uncommon. 
It usually occurs after 2 years of therapy hence long term usage requires ANA and 
liver function tests monitoring24. 
 
OTHERS: 
 Isoniazid 
 Hydantoins 
 Chlorpromazine 
 Methyldopa 
15 
 
 
 d- penicillamine 
 interferon alfa 
 
Cutaneous involvement in drug‐induced SLE may be the following: 
 vasculitic 
 bullous  
 erythema multiforme‐like  
 pyoderma gangrenosum like25 
 
 If a patient develops ANAs during drug treatment, the drug does not have 
to be stopped unless they have clinical features of the lupus syndrome.  
 
 Other drug include anticonvulsants, biological agents targeting TNF‐α that 
can produce ANA . In these patients, arthritis often predominates over cutaneous 
manifestations and some patients tolerate a switch to a different TNF inhibitor26. 
 
PATHOLOGY 
The primary lesions of SLE are  
 fibrinoid necrosis 
 collagen sclerosis 
 basophilic body formation 
 vascular endothelial thickening 
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 The basophilic (haematoxylin) bodies are homogenous and stain positively 
for DNA by the Feulgen technique. This material is similar to that of the 
homogeneous nuclear material of the  
 
LE cell (a neutrophil that has engulfed nuclear material from dying cells)27. 
Macroscopic appearances 
 Pleurisy  
 Pericarditis  
 Libman–Sacks endocarditis  
 Lymphadenopathy  
 Splenomegaly 
 
 Frequent macroscopic findings include pleurisy with adhesions and 
effusion, and pericarditis, especially if the patient has died with uraemia. The 
verrucose vegetations of Libman–Sacks endocarditis are diagnostic. These are 
small, firm, warty deposits, up to 0.5 cm in diameter, adherent to the valves of 
both sides of the heart and adjacent endocardium of the ventricles, chordae 
tendinae and on the papillary muscles28. 
 
Microscopic appearances 
 Immunoglobulins and complement at the dermal–epidermal junction in 
skin lesions (90%) and uninvolved skin (60%) 
 Haematoxylin bodies in the endocardium, renal glomeruli and elsewhere 
 Periarterial fibrosis of the spleen 
 Wire‐loop lesions in the kidneys27. 
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 Skin : The histopathology of the skin is similar in each of the different 
forms of LE‐specific skin disease (acute cutaneous LE, SCLE and CCLE). 
 
 There is immunoglobulin at the dermal–epidermal junction in SLE.  
 
 In acute cutaneous LE, there is a sparse dermal cellular infiltrate, focal 
liquefactive degeneration of the basal epidermis and upper dermal oedema. The 
dermal tissues may be oedematous, and sometimes vesicle formation occurs at the 
dermal–epidermal junction, with dilatation of the superficial vessels and 
perivascular lymphocytic infiltration.  
 
 Mucin may be found in the reticular dermis 29. All forms of cutaneous 
lupus have been shown to demonstrate an increase in the number of plasmacytoid 
dendritic cells and an increase in the expression of type 1 IFN‐related proteins 
such as MxA. Neutrophilic infiltrates, with dermal perivascular and interstitial 
neutrophils, including neutrophilic debris, have been recognized recently to form 
a cutaneous histological variant that can be indicative of systemic involvement in 
SLE30. 
 
Immunohistology 
 The lupus band test (LBT) was historically used as a diagnostic aid in 
SLE:  Immunoglobulins, predominantly IgG, but less frequently IgM and IgA, 
together with complement (C1q, C3) can be demonstrated at the dermal–
epidermal junction by immunofluorescence techniques. Such deposits were first 
described in lesional skin but are also present in clinically normal skin of SLE 
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subjects 31. Deposits occur more frequently in light‐exposed areas and are 
invariably present in acute lesions, although in early and late stages the test may 
be negative.  
 
 If IgG, IgM and IgA are all present, the diagnosis of SLE is likely, and the 
more common combination of IgG and IgM is also suggestive.  
 
 The basement membrane phenomenon can be demonstrated in uninvolved 
skin in three‐ quarters of active cases of SLE if the biopsy specimens are taken 
from the exposed skin, preferably from the dorsum of the wrist or forearm. Biopsy 
specimens from the unexposed skin are positive in only approximately 50% of 
patients, who may or may not have more severe renal disease and decreased long‐
term survival32. However, a positive LBT on uninvolved sun‐protected skin is a 
specific criterion for identifying patients with LE. In addition to dermal–
epidermal immunoreactant deposition, epidermal nuclear deposits, usually giving 
a speckled IgG pattern, occur in the basal epidermal nuclei and cells of the lower 
epidermis in nearly one‐third of patients33. 
 
Internal organs 
 The characteristic microscopic features in the internal organs include 
haematoxylin bodies in the heart valves and elsewhere, periarterial fibrosis of the 
spleen, and so‐called ‘wire‐loop’ lesions in the kidneys.  
 
 Lymph node enlargement is usually associated with retention of normal 
architecture, but sometimes necrosis and haematoxylin bodies may be found.  
19 
 
 
 
 Kidney disease is noted in up to 50% of patients with SLE and is the 
strongest overall predictor of morbidity and mortality 34. Decreased levels of C3 
and C4 correlate with active SLE and the presence of renal disease. The ‘wire‐
loop’ appearance in the kidneys is caused by thickening and hyalinization of the 
capillary basement membrane of the glomerular tufts. The changes in SLE are 
more likely to be localized to one part of the glomerulus. Thickening of the 
glomerular capillary basement membrane and alterations in reticular tissue in the 
media of arterioles are associated with deposits of IgG and C3. Lupus nephritis is 
classified into six types according to the location and extent of renal damage as 
detected by light microscopy, immunofluorescence and electron microscopy using 
the International Society of Nephrology (ISN) system35. 
 
Minimal mesangial lupus nephritis 
(class I) 
normal glomeruli by light microscope 
(LM) but mesangial immune deposits by 
immunoflouorescence 
Mesangial proliferative lupus nephritis 
(class II) 
mesangial hypercellularity with no 
subendothelial depositis by LM in 20% 
of cases; renal failure rare 
Focal lupus nephritis (class III) 
segmental and/or global endocapillary 
and/or extracapillary glomerulonephritis 
involving <50% of all glomeruli in 25% 
of cases; renal failure uncommon 
Diffuse (class IV) proliferative 
nephritis 
glomerulonephritis involving ≥50% of 
all glomeruli in 40% of cases; renal 
failure common 
Membranous nephritis (class V) 
global or segmental subendothelial 
deposits by LM in 10% of cases; renal 
failure uncommon 
Advanced sclerosing nephritis  
(class VI) ≥90% of glomeruli sclerosed 
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 All patients who develop glomerulonephritis (with active renal sediment) 
should have a renal biopsy to accurately stage disease and plan therapy 
 
Clinical features 
 The disease may affect almost any organ of the body, and can manifest in a 
broad variety 
1. Fever                                         90 
2. Arthritis and arthralgia          90 
3. Skin lesions                               80 
4. Renal involvement                   67 
5. Lymphadenopathy                   50 
6. Pleurisy                                      40 
7. Raynaud phenomenon               35 
8. Pericarditis                                 25 
9. Hepatomegaly                            25 
10. Central nervous system involvement  25 
11. Abdominal symptoms               20 
12. Splenomegaly                            15 
 
Men 
 Despite the female sex predominance, potential distinguishing features 
exist in organ involvement and prognosis between genders.  
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 Renal insufficiency/ failure is common and more severe  in men.  
 
 In one of the largest cohorts (Hopkins cohort), men were more likely to 
have haematological and serological manifestations with an increased risk of 
myocardial infarction, possibly due to an increased frequency of hypertension and 
positive lupus anticoagulant 36. 
 
 Men may also be more liable to seizures and have less skin disease. 
 
Presentation 
 The most commonly observed presenting symptoms are arthralgias 
followed by cutaneous involvement. Majority of manifestations occurred more 
frequently during the first 5 years of follow‐up 37. In fulminating cases there is 
usually marked constitutional disturbance, with fever, weight loss, anorexia, 
malaise and joint pains; the skin may be involved later, if at all.  
 
 On the other hand, the evolution can be gradual, starting with localized 
skin lesions and systemic involvement developing later. The diagnosis in many 
cases is made only by considering the condition in a patient with an obscure 
illness.  
 
 As most patients are female, sex is an important diagnostic point. 
Constitutional symptoms are common in patients with SLE and fatigue is reported 
in up to 80% of patients . Fever is common, particularly during active SLE . 
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Although weight loss is a feature in up to 50% of cases. Menstruation is irregular 
in 18% and absent in 75%38. 
 
 Late‐onset SLE, defined in the literature as onset >50 years, is uncommon. 
 
Cutaneous lesions 
LE SPECIFIC 
• Butterfly rash as part of ACLE                                   
• Subacute cutaneous LE               
• Chronic DLE                               
• Scarring DLE alopecia             
 
LE NON SPECIFIC        
• Non‐scarring alopecia                
• Chilblain lupus                           
• Mouth ulceration                        
• Bullous eruptions                        
• Photosensitivity                          
• Raynaud’s phenomenon             
• Chronic urticaria (>36 h)           
• Cutaneous vasculitis                    
• Livedo reticularis                         
• Episcleritis                                   
• Cheilitis 
• Facial oedema                             
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 Approximately 57–85% of patients have cutaneous findings at some stage. 
Non‐specific LE skin diseases are more frequently associated with SLE than LE‐
specific lesions and are characteristically associated with clinically significant 
SLE. 
 
Lupus‐specific changes  
 The LE‐specific changes can be divided into three groups based on the 
amount of time that the skin symptoms typically take to present. 
1. Chronic cutaneous LE (CCLE) 
2. Subacute cutaneous LE (SCLE) 
3. Acute cutaneous LE (ACLE). 
 
CCLE includes 
 localized and generalized DLE 
 hypertrophic LE 
 lupus profundus/panniculitis 
 lupus tumidus  
 
 The risk of SLE with localized versus generalized DLE is 5% versus 20% 
over time, whereas it is rarely seen with LE tumidus. Lupus panniculitis is 
reported to occur in approximately 2–3% of patients with SLE but, patients with 
lupus panniculitis may have up to 35% chance of a preceding, concurrent or 
subsequent diagnosis of SLE, thus these patients require to be followed closely for 
the development of systemic disease. 
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 Lesions resembling chronic discoid lesions are initial manifestations in 
approximately 10% of patients and occur in 20% of patients at some point in the 
disease course.  
 
 Chilblain LE is a rare form of CCLE. There is a familial form presenting in 
childhood, which is autosomal dominant  and a sporadic form usually affecting 
middle‐aged women. Up to 20% of patients with the perniotic lesions of chilblain 
lupus may go on to develop SLE39. 
 
SCLE includes 
 Annular 
 psoriasiform variants 
 
 Although the incidence of SLE in patients with SCLE is approximately 
50%, only 10–15% have serious organ involvement40. 
 
ACLE includes 
 lupus malar rash 
 bullous lupus  
 toxic epidermal necrolysis variant of SLE 
 maculopapular rash 
 photosensitive lupus rash  
 
 ACLE is often associated with active SLE. Cutaneous erythema is the most 
common feature, particularly on light‐exposed areas. 
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 In localized ACLE, a butterfly blush or discrete maculopapular eruption 
with fine scaling or oedema on the butterfly area of the cheeks is frequently 
found, typically sparing the nasolabial folds.  
 
 In generalized LE, a diffuse or papular erythema of the face, upper trunk 
and extremities is described that can resemble a viral exanthem or a drug eruption.  
Photosensitivity is very common. Sunlight may either precipitate or aggravate 
existing disease. UV radiation from fluorescent lighting as well as chronic 
exposure to indoor light sources are known to precipitate SLE. UV‐induced 
lesions of cutaneous LE are characterized by a latency period of up to several 
weeks, hence a negative history of photosensitivity does not exclude sensitivity. 
Systemic disease activity is increased in the 3–6 months following maximal sun 
exposure. 
 
 The rash in generalized LE and the generalized form of CCLE usually 
spares the distal interphalangeal, proximal interphalangeal and 
metacarpophalangeal joints – an important distinguishing feature from 
dermatomyositis41. 
 
 Occasionally, bullae may follow exposure to the sun, and bullae may be 
haemorrhagic. 
 
 Epidermal necrosis may give an appearance resembling TEN and this must 
be differentiated from drug‐induced TEN.  Patients with this form of cutaneous 
LE often have significant systemic disease activity such as cerebritis or nephritis. 
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 In other cases, lesions are like those of erythema multiforme (Rowell 
syndrome)41. 
 
Lupus non‐specifi c change 
 Erythema can be seen over the hyperthenar and hypothenar eminences of 
palms.  Reticulated palmar erythema may also be associated with vasculopathy of 
the antiphospholipid syndrome42.  
 
Non‐specific changes in the skin associated with SLE include 
 nail changes 
 hair changes 
 vasculitis 
 urticarial lesions  
 mucinoses 
 bullous lesions 
 mucosal lesions   
 
Nail changes43 
1. nail fold erythema 
2. splinter haemorrhages  
3. red lunula 
4. nail fold hyperkeratosis 
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 Other nail findings include nail ridging, onycholysis, onychomadesis and 
punctate or striate leukonychia caused by altered keratinization of the nail matrix. 
Blue‐black nail pigmentation due to disease or drugs for the disease  may also be 
obseved.  
 
 Capillaroscopy showing telangiectasias and erythema of the nail fold is 
sensitive for systemic disease activity. Capillary loop drop‐out and dilated 
capillaries are more commonly found in systemic sclerosis and dermatomyositis, 
is seen in patients with SLE and appears to be strongly correlated with the 
Raynaud phenomenon and anti‐U1 ‐ribonucleoprotein (anti‐U 1 ‐ RNP) 
antibodies. 
 
Hair changes44  
 The most common non‐specific skin manifestation of SLE is the diffuse, 
non‐scarring alopecia known as telogen effluvium, either as a transient 
phenomenon or during increased disease activity. LUPUS HAIR:  the alopecia 
can be chronic and associated with disease activity, leading to coarse, dry and 
fragile hair along the peripheral hairline during a systemic flare 2–3 months later, 
so‐called ‘lupus hair’. Alopecia areata is also seen rarely. Permanent scarring 
alopecia is similar to that found in DLE. 
 
Cutaneous vascular reactions44 45 
1. vasculitis -  primary inflammation of the vessel walls with secondary 
occlusion by fibrin 
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2. vasculopathy -  narrowing of the vessel walls or vessel lumen occlusion 
from thromboembolic disease 
 
 The distinction between the two conditions is important as their 
management is distinctly different.   
 
 Vasculitis : Arterioles and venules of any size of blood vessel may be 
affected in the skin. In SLE it usually presents as a small‐vessel leukocytoclastic 
vasculitis with palpable petechiae or purpura in dependent areas. Other causes 
such as drugs and infection should be excluded. The involvement of medium 
and/or large vessels may manifest as retiform or stellate purpura with or without 
necrosis and ulceration or as subcutaneous nodules. Other manifestations include 
gangrene, periungal infacts, splinter haemorrhages and urticarial and bullous 
changes. Gangrene of the fingers and toes may also develop either acutely or 
insidiously and can occur in patients with both vasculitis and vasculopathy due to 
thrombosis. 
 
Vasculopathy  
 Raynaud phenomenon3,46 has been observed to be a common non‐specific 
finding in SLE patients with vasculopathy. It is characterized by reversible 
vasospasm of the fingers and toes, often caused by cold exposure, with triphasic 
colour change; there is cold‐induced pallor, followed by cyanosis pain and 
numbness, then erythematous discoloration on rewarming. Predictors associated 
with LE and Raynaud phenomenon  include persistent periungual telangiectasia, 
involvement of the thumbs, ears, nose and toes, ice‐pick or pitted scarring of the 
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pulps and high ANAs, anti‐RNP and nucleolar antibodies. Raynaud phenomenon 
on in SLE is also associated with migraine and pulmonary artery hypertension. 
 
 Livedo reticularis is seen in up to 35% of SLE patient. It may be seen in 
patients with SLE both with and without the antiphospholipid syndrome . It 
presents as a fishnet‐like, mottled or bluish red discoloration, which blanches on 
pressure, most commonly on the buttocks and legs, followed by the outer aspects 
of the arms and less commonly on the trunk. The net‐like discoloration results 
from hypo‐oxygenation due to slow arterial blood flow in the dermal arterioles 
and the collection of the hypo‐oxygenated blood in the dermal venules. The 
appearance of livedo reticularis in patients with SLE and antiphospholipid 
syndrome may herald central nervous system involvement47.  
 
 Catastrophic antiphospholipid syndrome (CAPS) is rare (<1%), but has 
a high mortality of approximately 50% . CAPS presents in patients with APAb 
syndrome with a disseminated, intravascular coagulation‐ type picture with 
purpura fulminans. The diagnosis is made based on evidence of thrombosis in at 
least three organs, a histological finding of small‐vessel occlusion in at least one 
organ, a laboratory confirmation of APAbs and the rapid development of clinical 
manifestations48. 
 
 Atrophie blanche‐type lesions (painful, ivory, stellate scars on the lower 
extremities) may occur. Lesions similar to those in Degos disease porcelain‐white, 
atrophic macules with peripheral erythema and telangiectasia – may also occur in 
patients with APAbs . In SLE patients with Degos‐like lesions, a more benign 
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course is usual without the characteristic visceral involvement (digestive tract or 
central nervous system) that is commonly described in Degos syndrome49.  
 
Other skin lesions: 
 Lesions of primary anetoderma may also be seen. 
 
 Type II or III cryoglobulinaemia50, usually presents with palpable purpura 
of a small‐vessel vasculitis, with ulceration and necrosis in severe cases. 
 
 Cholesterol emboli with  purpuric infarction of the tips of the fingers or 
toes.  
 
 Calciphylaxis may also occur in patients with SLE and end‐stage renal 
disease. 
 
 Erythromelalgia is characterized by burning pain in the hands and feet 
aggravated by heat and dependence and accompanied by erythema and 
warmth. It can be primary or secondary (e.g. underlying SLE or blood 
dyscrasias) and is thought to be caused by microvascular arteriovenous 
shunting. 
 
 Urticaria51: Urticarial lesion,  hypocomplementaemic urticarial vasculitis 
can also be seen. 
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 Mucinosis52: Papular or nodular lesions resulting from mucinous deposits 
in the dermis (papulonodular mucinosis) without microscopic features of 
LE have been reported. 
 
 Dystrophic calcinosis is rare, but has been reported. 
 
Pigmentary changes 
 Hypopigmentation may result from both SCLE and DLE. In addition, a 
bluish black pigmentation of the skin may result from antimalarial therapy due to 
trapped hemosiderin53.  
 
Bullous lesions54  
Blistering is uncommon in SLE and can be divided into three categories: 
 
1) Subepidermal bullae in SCLE and ACLE lesions due to separation of the 
epidermis and dermis as a result of severe liquefaction degeneration of the 
basal layer and dermal oedema (TEN like ACLE and Rowell syndrome). 
2) SLE‐associated autoimmune bullous disease including dermatitis 
herpetiformis, pemphigus vulgaris (so‐called pemphigus erythematosus), 
pemphigus foliaceus, paraneoplastic pemphigus, bullous pemphigoid, 
pseudoporphria, epidermolysis bullosa acquisita and IgA disease. 
3) A separate subset, bullous SLE (BSLE), is a distinct type of nonspecific, 
autoantibody‐mediated, cutaneous SLE that results in a subepidermal 
blister. 
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The diagnosis of BSLE requires the presence of:  
(i) SLE 
(ii) vesiculobullous eruption arising but not limited to sun‐exposed skin  
(iii) histopathological subepidermal blisters and neutrophilic upper dermal 
infiltrates 
(iv) immunoglobulin and complement deposition at the basement‐
membrane zone with direct immunofluorescence.  
 
 DIF demonstrates linear IgG (± IgA and IgM or C3) deposits at the 
basement‐membrane zone, contrasting with the granular immunostaining seen in 
LE interface dermatitis. Evidence of antibodies to type VII collagen can be 
demonstrated by indirect immunofluorescence. 
 
 Clinically, the bullous lesions arise predominantly on normal or 
erythematous sun‐exposed or flexural skin, but they may be more widespread, and 
can heal with milia formation . Blistering often parallels systemic flares of SLE, 
particularly affecting the kidneys. Dapsone either alone or in combination with 
prednisolone is the treatment of choice. 
 
 Pemphigus erythematosus55 combines the immunological features of 
pemphigus and LE and presents with erythematous, scaly, hyperkeratotic or 
crusted lesions, sometimes adversely affected by the sun. The lesions occur in a 
butterfly  distribution on the cheeks and in a seborrhoeic distribution on the trunk 
of patients with Senear–Usher syndrome. DIF demonstrates immunoglobulin and 
complement in the intercellular substance and at the dermal– epidermal junction 
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of perilesional and, to a lesser extent, of light‐exposed and non‐exposed skin. 
Circulating pemphigus‐like antibodies and antinuclear factor occur in 80–100% of 
patients, but anti‐DNA and ENA antibodies are not found. 
 
Mucous membrane lesions55  
 Oral and naso‐pharyngeal ulcers are one of the SLICC criteria for 
identifying patients with SLE and are associated with increased disease activity. 
These lesions are often nonspecific, shallow and tend to occur in crops. LE ulcers 
are usually non‐painful and commonly affect the hard palate. Non‐ LE ulcers such 
as those in recurrent aphthous stomatitis, which affects up to 20% of the general 
population, are usually painful and range from a few millimetres in size (minor) to 
centimetres (major). Mucous membrane lesions can also occur in the context of 
DLE. Lesions can be of three types: 
 
 erythematous lesions (erythematous macules, palatal erythema, ulcers, 
blisters or erosions) 
 discoid lesions and ulcers (as erythematous central areas surrounded by 
well‐demarcated, irregular, white borders and telangiectasia) 
 may coexist  
 
 Histologically, a lymphocyte‐rich interface mucositis is seen. Mucosal 
biopsy should be considered in any nonhealing or irregularly ulcerated lesion. 
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Differential diagnosis 
SLE, ‘the great mimicker’.  
 Connective tissue diseases - rheumatoid arthritis, mixed connective tissue 
disease, undifferentiated connective tissue disease, amyopathic 
dermatomyositis, 
 Kikuchi–Fujimoto disease 
 Acute viral syndromes (parvovirus, Epstein–Barr virus, infectious 
mononucleosis, HIV), 
 Behçet disease 
 Familial Mediterranean fever 
 Drug‐induced lupus 
 
 Coexistent autoimmune diseases such as APAb syndrome, rheumatoid 
arthritis, scleroderma, Sjögren syndrome, autoimmune hepatitis, psoriasis, 
primary biliary sclerosis, thyroid disorders and diabetes may complicate the 
diagnosis as up to one‐third of patients have other autoimmune diseases. 
 
Complications and co‐morbidities 
 Arthritis56,57: Involvement of the joints occurs in approximately 90% of 
patients, arthralgia being more common than arthritis. There is marked soft‐tissue 
swelling, especially of the dorsa of the fingers, hands and wrists, although joint 
erosions on X‐ray are not a feature. The deformity is usually less, but the soft 
tissue swelling is more marked than in rheumatoid arthritis. Rarely, erosive 
symmetrical polyarthritis with rheumatoid arthritis‐like deformities, termed 
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rhupus, can occur with the  presence of anticyclic citrullinated peptide antibodies. 
Jaccoud arthropathy is seen in few patients, which is a  severe deformity of the 
hands with ulnar deviation and swan‐neck configuration, often with little pain and 
good function. The progressive rheumatoid arthritis‐like deformities in this 
syndrome are due to tenosynovitis rather than the synovial inflammation seen in 
rheumatoid arthritis. Tendinopathy may result in tendon rupture. The elbows, 
shoulders, knees and feet may also be involved and soft‐tissue nodules may occur, 
usually indicating calcinosis. 
 
 Muscle changes57: Muscle pain occurs in approximately 50% of patients, 
and this may be confused with the pain of arthritis. It can be related to steroid 
myopathy or other drug effects. Inflammatory myopathy occurs in 5–10% of 
patients. 
 
 Bone change57: Avascular necrosis of the bones occurs in 5–30% of 
patients with SLE. Risk factors include the presence of the Raynaud phenomenon, 
vasculitis, antiphospholipid syndrome and glucocorticoid use. The femoral head 
or condyle is most frequently involved, but the condition also may involve the 
knees, ankles, humerus, metatarsals and carpal bones. It is commonly bilateral, 
with involvement of multiple joints. Osteoporosis with its consequent increased 
fracture risk is another important bone‐related problem in SLE . The prevalence of 
osteoporosis may attain 50%, with fractures occurring in up to 20% of individuals 
with SLE. Factors contributing to bone loss include chronic inflammation, 
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glucocorticoid use, renal dysfunction, vitamin D deficiency, ovarian failure and 
concomitant thyroid disease. The identification of risk factors, regular bone 
mineral density measurement and appropriate therapy are critical. 
 
 Heart58:  Cardiovascular disease is one of the main prognostic predictors 
in SLE and is responsible for the increase in late mortality of the disease. Pleurisy 
and pericarditis commonly occur. Clinically significant  Libman–Sacks 
endocarditis occurs in just 1–2% of patients. The valves on the left side of the 
heart are commonly involved. Coronary artery disease is the most common cause 
of death in patients with longstanding SLE. The presence of APAbs  may predict 
atherosclerosis independently of other risk factors. Young women with SLE are at 
an increased risk of developing myocardial infarction. Treatment with 
corticosteroids increases the risk of developing coronary artery disease by 
contributing to hyperlipidaemia, hypertension and weight gain. 
 
 Lungs59: Transient pleurisy is the most common feature with pleural 
thickening. Lungs show transient infiltration, sometimes with mottling and 
reticulation. Acute pneumonitis with severe dyspnoea and fever is rare. Shrinking 
lung syndrome is a condition that is typical of SLE and that consists of a 
restrictive lung disease without parenchymal changes but with decreased lung 
volumes associated with elevated hemidiaphragms and basal atelectasis on 
radiography. 
 
 Renal changes60: Renal disease in lupus accounts for 3% of end‐stage 
renal failure, and is an important cause of mortality in SLE. The need for regular 
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screening by urinalysis, blood pressure monitoring, assessment of renal function 
and early renal biopsy is critical. Renal exacerbations are associated with high 
titres of antinuclear factor, elevated DNA binding and low serum complement. 
 
 The course is variable, and albuminuria and casts may persist for years 
without marked deterioration in renal function. Kidney damage, if this is going to 
develop, usually appears early (within the first 3 years) and is more frequent and 
severe in younger patients. A renal biopsy in every patient with haematuria, 
proteinuria or elevation of serum creatinine is advised. 
 
 Gastrointestinal tract61: Gastrointestinal symptoms are usually mild with 
anorexia, nausea and vomiting being the most frequent. In patients with active 
SLE and abdominal pain, vasculitis may be present requiring comprehensive and 
aggressive evaluation including complete blood count, amylase, blood chemistry 
and abdominal radiography is required. Oesophageal dysmotility is common, 
resulting in heartburn and regurgitation. 
 
 Hepatic lesions62: Liver disease  is usually mild and often asymptomatic. 
Lesions include granulomatous hepatitis, chronic active hepatitis and cirrhosis. 
There may be a link between antiribosomal P antibody and SLE‐associated 
hepatitis. Autoimmune hepatitis is diagnosed by the presence of interface 
hepatitis, hypergammaglobulinaemia and the presence of autoantibodies. Type 1 
autoimmune hepatitis, previously named ‘lupoid hepatitis’, mainly involves young 
women who have antibodies to smooth muscle. 
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 Thyroid disease63: Both hyperthyroidism and hypothyroidism occur in 
SLE, and there is a high frequency of abnormal thyroid function tests and thyroid 
autoantibodies in patients without diagnosed thyroid disease. 
 
 Nervous system: The involvement of the nervous system by SLE results in 
neurological and psychiatric manifestions. The ACR produced a standard 
nomenclature and case definitions for 19 neuropsychiatric syndromes known to 
occur in patients with SLE. In decreasing order of frequency these are cognitive 
dysfunction (55–80%), headache, mood disorders, cerebrovascular disease, 
seizures, polyneurophathy, anxiety and psychosis (0–8%). Primary proposed 
mechanisms include vascular occlusion or haemorrhage, autoantibody‐mediated 
effects and cytokine effects. Neuropsychiatric events commonly occur within the 
first year after SLE diagnosis and in the presence of generalized disease activity. 
Peripheral sensorimotor and autonomic neuropathy occurs, brought about by 
vasculitis in the vasa nervorum. Antiribosomal P antibodies have been associated 
with psychiatric SLE64. 
 
 Ocular changes65: The most common ocular manifestation is dry eyes or 
keratoconjuntivitis sicca caused by secondary Sjögren syndrome. Retinal 
vasculopathy in the form of cottonwool spots is the next most common 
manifestation and suggests active SLE and lupus cerebritis. Optic neuropathy is 
associated with a poor visual prognosis. Other ocular manifestations include 
episcleritis and scleritis, keratitis secondary to keratoconjuntivitis sicca, uveitis, 
orbital inflammation, antimalarial toxicity and APAb retinopathy. 
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 Ears: Sudden sensorineural hearing loss may occur in patients with SLE 
and may be associated with the antiphospholipid syndrome requiring treatment 
with anticoagulation. 
 
SLE IN CHILDHOOD  
 15–20% of SLE has its onset in childhood . The clinical picture, course and 
treatment are similar to the disorder in adults, but on the whole children have 
more severe disease. A meta‐analysis of 16 studies comparing the clinical features 
of childhood‐ versus adult‐onset SLE demonstrated that malar rash, 
mucocutaneous involvement, haematological abnormalities, seizures, renal 
involvement, urinary cellular casts and proteinuria, adenopathy and fever were 
more common in children66. 
 
SLE IN THE ELDERLY 
 The onset of disease over 50 years of age occurs in nearly 12–18% of 
patients. There is an increased incidence of Raynaud syndrome, sicca symptoms 
and pleuritis. There is also increased accumulated damage and morbidity despite a 
reduced incidence of renal disease. 
  
 Antibodies to Ro and La are frequent and there appears to be an association 
with HLA‐DR367. 
 
SLE IN PREGNANCY 
 Fertility is normal if renal function is good. Worsening of SLE is 
uncommon in pregnancy, especially in those on immunosuppressive therapy. 
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Clinical remission or minimal lupus activity in the 6 months before conception 
lowers the chances of a significant flare and should indicatean uncomplicated 
pregnancy and a live birth. Active lupus nephritis poses the greatest risk to 
pregnancy outcomes in lupus, with a history of lupus nephritis posing a risk of 8–
36% of nonelective pregnancy loss68. Up to 20% will be affected by pre‐
eclampsia, one‐third will have preterm delivery and another third will have a 
caesarian section. The increased risk of fetal death may be because of immune 
complex deposition on the trophoblast basement membrane or the transplacental 
passage of APAbs. Antiphospholipid syndrome, may lead to an increased rate of 
fetal loss in 45–90% of pregnancies. This falls considerably to less than 30% if 
treatment is given with prophylactic low‐molecular‐ weight heparin (LMWH) and 
low‐dose aspirin for women with APAbs and a history of pregnancy 
complications. Similarly for women with APAbs and a history of vascular 
thrombosis, treatment with full‐dose LMWH and low‐dose aspirin is indicated, 
with no treatment recommended for those women with APAbs only. 
 
 Regarding management of lupus during pregnancy, oral corticosteroids are 
relatively safe. Side effects include a small absolute risk of cleft lip or palate and, 
as in women who are not pregnant, an increased risk of maternal hypertension and 
diabetes. Steroids may also need to be temporarily increased at the time of 
delivery and postpartum. Mycophenolate mofetil is contraindicated and it is 
recommended that women transfer to an alternate immunosuppression prior to 
conception, such as azathioprine. Hydroxychloroquine may be continued and 
there is evidence that it can reduce disease flares and may decrease the risk of 
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recurrent cardiac neonatal lupus and heart block in mothers with anti‐Ro 
antibodies. The use of oral contraceptives in women with stable disease does not 
increase the risk of flare. However, oestrogen‐containing contraceptives should be 
avoided in lupus patients with positive anticardiolipin ± lupus anticoagulant. The 
progesterone‐only contraceptive Depo‐Provera is an alternative option, although 
its use for more than 2 years may increase the risk of osteoporosis. Breastfeeding 
is probably safe if the patient is on aspirin, low‐dose steroids or 
hydroxychloroquine, but should probably be avoided if other immunosuppressives 
are used69. 
 
Association with other diseases.  
 SLE can occur concurrently with other connective tissue diseases such as 
rheumatoid arthritis – so‐called rhupus, as described by Shur. Systemic sclerosis 
and SLE may occur in the same patient and a subset of patients with scleroderma 
and antitopoisomerase and anti‐U1 ‐RNP antibodies who share a high lupus‐like 
IFN gene expression pattern. SLE occurs rarely in association with lichen 
sclerosus, with ‘en coup de sabre’ morphoea and linear and plaque morphoea. 
Secondary Sjögren syndrome can also occur in SLE  and is associated with older 
age, a higher prevalence of Raynaud phenomenon, rheumatoid factor and anti‐Ro 
and anti‐La antibodies70. 
 
Disease course and prognosis 
 Survival is related to organ involvement and to the frequency of 
exacerbations. The highest mortality rates were seen in female patients, those of 
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younger age, those with SLE duration <1 year and those of black/African 
American race. Exacerbations are more frequent in the first 5 years of the disease. 
Pregnancy does not affect long‐term survival. Prolonged survival is associated 
with an increased risk of atherosclerosis, avascular necrosis and neuropsychiatric 
dysfunction. In elderly people the presentation is insidious and the clinical course 
is relatively benign. Renal disease and serological abnormalities are less frequent, 
and arthritis, with subcutaneous nodules, and pleuropericarditis are more 
prominent in elderly people. Causes of death include renal disease, severe lupus 
disease activity, infection and cardiovascular disease. In the SLICC multicentre 
international cohort study,  an increased mortality from haematological cancers 
such as non‐Hodgkin lymphoma and lung cancer but a decreased mortality from 
breast cancer was observed71. 
 
Investigations 
 A skin biopsy is often necessary to confirm the diagnosis. Biopsy for DIF 
is unnecessary if the case is diagnostic and may indeed be false positive if taken 
from photo‐exposed skin72. 
 
 A lupus band test, done on unaffected non‐sun‐exposed skin is mainly of 
historic interest nowadays due to the current serological tests available73. 
 
 Complete blood count  shows anemia as the most frequent finding. The 
most prevalent type is anaemia of chronic disease; however iron deficiency, 
autoimmune haemolytic anaemia (AIHA), drug induced myelotoxicity and 
anaemia of chronic renal disease are less common causes.  
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 Leukopenia occurs in roughly 50% of patients with SLE. More 
specifically, lymphopenia has been reported in one study with a cumulative 
frequency of up to 93%.  
 
 Thrombocytopenia (platelets <100 000/mm2 ) is a common clinical 
manifestation in SLE, present in up to 37% of patients and correlates with 
increased morbidity and cumulative damage. 
 
 The ESR is raised at some time in nearly 90% of patients; C‐reactive 
protein is usually normal in the absence of infection, however an elevated level 
may also indicate disease activity so these values should be interpreted in 
context74.  
 
 Direct coombs test: In AIHA, a positive direct antiglobulin test (Coombs’ 
test) in the context of haemolyic anaemia generally confirms the diagnosis. 
 
 Protiens: Polyclonal gammopathy is commonly observed in patients with 
SLE and is an indication of an autoimmune reaction. Hypoalbuminaemia is also 
reported in 30–50% of patients and the measurement of baseline immunoglobulins 
may help diagnose primary or secondary immunodeficiencies associated with 
SLE and treatment, respectively. IgE antibodies may be raised and may correlate 
with disease activity including nephritis in SLE.  
 
 False positive serological tests for syphilis are found in approximately 25% 
of patients. 
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 The lupus anticoagulant is one of a number of APAbs found in up to 15–
34% of patients with SLE, with anticardiolipin antibody in upto 30%73. 
 
 The LE cell phenomenon, is the basis for the LE cell test, which is 
positive in over 80% of patients. LE cells are neutrophils that have engulfed the 
nuclear material from degenerative white cells in the presence of an antibody to 
deoxyribonucleoprotein (the LE cell factor).  Sometimes, large masses of nuclear 
material are found extracellularly and, with surrounding leukocytes, form rosettes. 
LE cells, if present in large numbers, are highly suggestive of SLE. A positive LE 
cell test is also a feature of drug‐induced LE. The LE cell test has now been 
superseded by tests for antinuclear factors and anti‐DNA antibodies75. 
 
ANA -  anti nuclear antibodies  
 Following clinical assessment, if the pretest probability of SLE is high, 
ANA testing is ordered to support the diagnosis. This test is 95–100% sensitive 
for the diagnosis of SLE. Autoantibodies have been noted a mean of 3.3 years 
prior to diagnosis in a cohort study who ultimately developed SLE. The term 
undifferentiated connective tissue disease may be used in patients with 
symptoms suggestive of SLE but not yet clearly ascribable to SLE. 
 
 ANA positivity is central to the diagnosis of SLE yet patients may be 
diagnosed without a positive ANA test. The incidence of ANA negative SLE has 
been estimated to be 1–5%. Currently, if an ELISA test or solid phase assay was 
used and the clinician’s suspicion for SLE was strong, the ANA test with 
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immunofluorescence is recommended. The ‘lupus band test’, or demonstration of 
immunoreactants at the dermal–epidermal junction, may be of benefit in 
confirming the diagnosis of SLE in select cases where the ANA test may be 
equivocal. 
 
 One or more ANAs can be detected by fluorescent antibody techniques in 
over 80% of cases. The incidence depends on the substrate used. Most 
laboratories now use human cell lines for antibody testing, particularly Hep‐2 
cells derived from a human laryngeal cell line76. Four patterns commonly seen 
are: 
 
1) The homogeneous pattern , produced by antinucleohistone, the nuclei are 
stained all over (common) 
2) The speckled pattern shows minute points of fluorescence scattered all 
over the nucleus, the antigens being saline‐soluble proteins. 
3) The nucleolar pattern shows uniform staining of each nucleolus 
(occasional) 
4) The membranous pattern in which staining occurs at the periphery of the 
nucleusis seen in sera containing anti‐DNA antibody (active disease) 
 
 More than one antibody may be present in a single serum, usually in 
different titres. 
 
 Homogeneous antinuclear factor (which is the same factor as the LE cell 
factor, although the fluorescent antibody test is more sensitive than the LE cell 
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test) is more than twice as common as the speckled factor, but antinucleolar 
antibody is only occasionally found. The peripheral factor is present in high titre 
in more than 50% of cases in the active phase of the disease and is infrequent in 
other diseases. The so‐called shrunken peripheral pattern is thought to be 
associated with a poor prognosis and a high incidence of renal disease. It may 
appear 10–15 days  before an exacerbation of the disease and be associated with a 
fall in serum complement. Any person in apparently good health found to have a 
high titre of antinuclear factor should be followed up for years as there is a 
considerable likelihood of developing LE or systemic sclerosis. 
 
Other patterns 
 When Hep‐2 cells are used as substrate, as well as being more sensitive to 
the presence of ANA, further patterns can be identified. These include centromere 
staining associated with the CREST syndrome (calcinosis, Raynaud syndrome, 
oesophageal involvement, sclerodactyly and telangiectasia) and, in 6% of patients 
with SLE, homogeneous, peripheral (specific to SLE), fine and coarse speckles 
and a ground‐glass appearance produced by the Scl‐70 antibody found in systemic 
sclerosis. There are also several patterns of nucleolar staining: homogeneous, 
speckled and clumpy.  
 
 Anti DNA antibodies77 are almost always present in active disease.  
Levels often correlate with disease activity; changes in anti‐dsDNA antibody titres 
sometimes correlate with disease activity and lupus nephritis and can be useful in 
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monitoring disease activity. High (>200 IU/mL) titres of anti‐dsDNA have been 
shown to be an independent predictor of moderate to severe SLE flares. 
 
 Anti‐ Smith (anti‐Sm) antibodies78 are present in approximately 30% of 
patients with SLE, but are considered specific for the disease and are included in 
the ACR criteria, although they are not of use in monitoring overall lupus disease 
activity. The association of anti‐Sm and organ involvement is reported to included 
nephritis, neuropsychiatric lupus, pulmonary fibrosis, serositis and peripheral 
neuropathy.  
 
 Antihistone antibodies are associated with drug‐induced lupus but are of 
limited value in the diagnosis or clinical assessment of patients with SLE. 
 
 Anti‐RNP antibodies are seen in approximately 23–40% of patients and is 
characteristic of mixed connective tissue disease. Amongst patients with SLE, the 
presence of anti‐RNP antibodies does not predict neuropsychiatric manifestations 
or lupus nephritis or other manifesations of SLE. 
 
 Anti‐Ro antibody occurs in approximately 30–40% of patients, who have 
an increased tendency to photosensitivity, secondary Sjögren syndrome, 
interstitial pneumonitis, shrinking lung syndrome or deforming arthropathy, as 
well as being a marker for neonatal lupus. It is also found in 60–90% of patients 
with SCLE as well as ANA‐negative SLE patients and lupus like syndromes with 
genetic deficiencies of C1q, C2 or C4. 
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 Anti‐La antibody to another RNP product of RNA polymerase III, is 
present in 10–15% of patients, often with Sjögren syndrome and with anti‐Ro 
antibody. Anti‐Ro and anti‐La antibodies should be tested in any female patient 
with SLE, mixed connective tissue disease, Sjogren syndrome or other systemic 
rheumatology conditions who is planning a pregnancy because of the increased 
risk of neonatal lupus syndrome. 
 
 Although several different antibodies occur in the same patient, they 
fluctuate independently, and the antibody profile may alter over the years.  
 
 The only characteristic pattern of antibody appears to occur in the LE–
erythema multiforme syndrome, in which there is a speckled type of antinuclear 
factor, a specific precipitating antibody (anti‐ La) and rheumatoid factor. This 
syndrome is occasionally found in cases of SLE as well as DLE. 
 
Antinuclear antibody‐negative SLE 
 These patients present with cutaneous findings similar to SCLE, positive 
anti‐Ro antibodies and photosensitivity. Clinically, a non‐scarring malar flush, 
oral ulceration and photosensitivity, with papulosquamous or annular lesions on 
the face, trunk and arms, are prominent, but arthritis, serositis, renal disease and 
haematological involvement are less frequent than expected in SLE.  
 
 In approximately 5–10% of patients with SLE, antinuclear factor cannot be 
demonstrated using standard substrates such as rat or mouse liver. This is a 
problem in less than 2% if Hep‐2 cells are used. Over 60% of patients have anti‐ 
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Ro antibodies and approximately one‐third have anti‐La antibody. Twenty‐five 
per cent have antibodies to single‐stranded DNA. Approximately 10% of patients 
eventually become positive for antinuclear factor79. 
 
 Cryoglobulins may be found in 11% of patients. Cryoglobulinaemia may 
precede the manifestations of SLE by many years. Cold agglutinins occur in 6%.  
 
 Complements: Inherited deficiencies of the major complement 
components may occur in SLE. Patients with homozygous deficiencies in the C1, 
C2 and C4 early components of the classic pathway are particularly at risk. The 
most common is homozygous C2 deficiency in which SLE occurs in 
approximately 30% of patients. It shows a low incidence of renal disease, but 
more cutaneous involvement and arthralgia. Serum antinuclear antibodies and 
anti‐dsDNA antibodies are often lower in patients with complement deficiency 
associated SLE, compared with idiopathic SLE, however anti‐Ro antibodies 
appear more frequent. Patients with isolated C1q deficiency patients may be 
helped by danazol. 
 
Assessment of disease activity 
 The Cutaneous Lupus Erythematosus Disease area and Severity Index 
(CLASI) has been described for the assessment of cutaneous disease. CLASI 
activity and damage scores correlated with physician‐assessed cutaneous activity. 
The CLASI provides a quantitative measure of the skin‐specific burden of disease, 
allowing for standardized measurements of disease progression. It also 
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distinguishes clearly between activity and damage, which is important for disease 
management80. 
 
Management 
 The choice is individualized and depends on the degree of organ 
involvement and disease severity. It is important to assess the patient’s progress 
by general well‐being and relief of symptoms rather than by strict attention to 
laboratory abnormalities. The ESR and DNA antibodies are variable and a poor 
guide to the adequacy of therapy and the titre of ANAs often persists unchanged 
despite clinical remission81. Anti‐dsDNA antibody and serum complement levels 
may be helpful in predicting exacerbations. 
 
The management of SLE can be divided into 
1. non‐pharmacological 
2.  pharmacological 
 
NON PHARMACOLOGICAL 
General measures for SLE patients should include avoidance of sun exposure. 
 Patients should be advised to wear broad‐brimmed hats 
 To cover the ‘V’ of the neck and the arms  
 To  use a sunscreen with a sun protection factor of at least 55 as patients. 
 
 Sunscreen with avobenzone (blocks UVA‐1), titanium dioxide or zinc 
oxide (block UVB and UVA‐1) are also recommended to block longer UVA 
wavelengths. 
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 Smoking cessation should also be encouraged as cigarette smoking may 
exacerbate the disease and to prevent the increased risk of accelerated 
atherosclerosis   
 A low‐fat, high‐marine‐oil diet (eicosapentaenoic acid: Maxepa 20 g/day) 
modified disease activity 
 
PHARMACOLOGICAL  
 It is important to monitor serum 25‐hydroxy vitamin D at baseline and to 
treat appropriately to ensure that recommended minimum serum levels of 30 
ng/mL (75 mmol/L) are achieved [ 387,388 ]. To correct vitamin D deficiency, 
1000 IU per day of oral vitamin D3 (cholecalciferol) is recommended as this is 
more effective than vitamin D2. Symptomatic therapy for joint pain using non‐
steroidal anti‐inflammatory drugs is valuable. 
 
Cutaneous lesions 
 For skin disease alone, topical therapy is an appropriate first line treatment 
or adjunct for individual lesions.  
 
 Topical corticosteroids 
 Clobetasol propionate 0.05% 
 Betamethasone valerate 0.1% 
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 Potency depends on the site, but generally potent fluorinated steroids 
should only be used for short periods on very inflammatory lesions on the face 
because of the risk of atrophy and telangiectasia, with 1–2.5% hydrocortisone 
used afterwards82. 
 
 Topical calineurin inhibitors: Tacrolimus and pimecrolimus may be equally 
efficacious when compared with clobetasol propionate 0.05% and betamethasone 
valerate 0.1% respectively, particularly for tumid lupus.  
 
Intralesional calcineurin inhibitor 
 Intralesional triamcinolone acetonide (2.5–5 mg/mL) may also be useful 
for individual lesions, particularly on the scalp.  
 
 Antimalarials: For patients with extensive or resistant disease, antimalarials 
are used. The use of the antimalarials chloroquine or hydroxychloroquine in mild 
disease must be encouraged. They prevent lupus flares and increase the long‐term 
survival of patients. 
 
 Antimalarials have also been found to work synergistically with 
mycophenolate mofetil for the treatment of membraneous nephritis and are 
recommended by both the ACR and the European League Against Rheumatism 
(EULAR) guidelines for patients with lupus nephritis.  
 
 Additionally, they have a modest effect on lipid profile, cardiovascular 
disease and thrombotic risk. Hydroxychloroquine in particular has been found to 
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decrease lupus activity in pregnancy without harming the baby. Quinacrine is 
contraindicated in pregnancy as it crosses the placenta83. 
 
 Corticosteroids: Dosage depends on the degree of organ involvement and 
disease severity. 
 
 Low‐dose oral prednisolone (0.1–0.2 mg/kg) may be useful in patients with 
mild SLE and musculoskeletal manifestations resistant to other therapies.  
 
 High doses of oral prednisolone (1–1.5 mg/kg) or IV methylprednisolone 1 
g daily for 3 days (pulse therapy) may be useful for severe disease with major 
organ involvement (e.g. renal, systemic vasculitis or neurological involvement). 
 
 Once the condition appears to be under control, the dosage may be reduced 
until a maintenance dose is reached, ideally <6 mg, as the Hopkins lupus cohort 
have demonstrated that doses of greater than 6 mg increase the risk of organ 
damage by more than 50%. A single daily dose given in the morning produces 
fewer side effects and does not impair the therapeutic response.  
 
 Steroid myopathy, steroid induced psychosis which is difficult to 
differentiate from SLE neuropsychiatric manifestions can occur with high‐dose 
steroids84. 
 
Immunosuppresives 
 For more severe disease, immunosuppressive drugs are used to minimize 
the risk of damage and to act as steroid‐sparing agents. The long‐term risk of 
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malignancy must be considered. Cyclophosphamide has been associated with 
bladder cancer, myelodsplastic syndromes, haematological malignancies, cervical 
atypia and skin cancers. Mesna may reduce urotoxic side effects. For induction 
therapy in lupus nephritis, pulsed IV cyclophosphamide is preferred to oral 
cyclophosphamide due to reduced toxicity, particularly bladder injury and may be 
followed by mycophenolate mofetil or azathioprine (the former may be more 
efficacious as maintenance therapy). 
 
 Azathioprine is associated with the development of lymphomas and an 
increased risk of human papillomavirus‐related premalignant and malignant 
lesions. Because of its slower onset of action, azathioprine is often used as a 
steroid‐sparing agent and as a maintenance drug following the control of more 
acute SLE. It has also been reported to be effective in severe cutaneous disease 
and in the treatment of chronic active hepatitis complicating lupus. 
 
 Mycophenolate is contraindicated in pregnancy and in patients wishing to 
become pregnant; a transition from mycophenolate mofetil to azathioprine should 
be made in the preceding months because of the teratogenic risk. Mycophenolate 
mofetil may also be used as an alternative for induction treatment of mild to 
moderate lupus nephritis with similar efficacy to cyclophosphamide. 
 
 Methotrexate is teratogenic and contraindicated in women within 3 months 
of planned conception. It is  a useful adjunct in patients with mild to moderate 
SLE and recalcitrant mucocutaneous lesions and musculosketal symptoms (7.5 – 
20 mg/week) 
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 Intravenous immunoglobulin is a useful adjunct in resistant skin disease.  
Ciclosporin has been used in resistant cases and for non‐renal lupus. 
 
Other potential treatments include: 
 Leflunomide therapy, which is more commonly used in rheumatoid 
arthritis. Plasmapheresis may be useful in managing life‐threateningcomplications 
such as fulminating  vasculitis or central nervous system disease or for renal 
disease that is resistant to corticosteroid or cytotoxic therapy86.  
 
 UVA‐1 (340–400 mm) has been shown to have modest effects on 
cutaneous lesions87.  
 
 Lupus nonspecific skin eruptions dapsone may be useful for the treatment 
of urticarial lesions and bullous eruptions85. 
 
Biological 
 Rituximab (monoclonal antibody to CD20) 
 Belimumab (a B‐lymphocyte stimulator inhibitor). Antibody 
 Tocilizumab (monoclonal antibody to IL‐6 receptor) 
 Abatacept (the T‐cell inhibitor) 
 
 Both the ACR and EULAR support the use of rituximab in the treatment of 
refractory nephritis. Belimumab has also been shown to improve overall SLE 
activity, particularly mucocutaneous and musculoskeletal lesions.  
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 There are ongoing studies investigating inhibitors of  IFN pathway 
including the monoclonal antibodies that target IFN‐α, sifalimumab and 
rontalizumab88,89. 
 
  
Aims & objectives 
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AIMS AND OBJECTIVES 
 
To determine the following in the cases of SLE 
1. Age incidence 
2. Sex incidence 
3. Precipitating factors 
4. To asses the various types of cutaneous lesions in patients with SLE 
5. To evaluate the relation between skin lesions and other systemic 
involvement 
 
  
Methodology 
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MATERIALS AND METHODS 
 
4.1 Study design: 
 Cross sectional observational study 
 
4.2 Study approval: 
 Prior to commencement of this study – Thesis & Ethical Committee of 
Madras Medical College had approved the thesis protocol. 
 
4.3 Place of study:   
 Rajiv Gandhi Government General Hospital 
 
4.4 Period of study: 
 November 2016 to September 2017 
 
4.5 Sample size:  
 50 cases or more 
 
4.6 Inclusion criteria: 
 All patients with SLE attending Dermatology Outpatient Department and 
from Rheumatology Department, Rajiv Gandhi Government General Hospital. 
 
4.7 Exclusion criteria:  
 Cutaneous lesions such as folliculitis, candidiasis, tinea corporis, scabies 
and drug rash. 
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4.8 Methodology 
 This study was conducted from November 2016 to September 2017.  The 
sampling procedure is summarized as follows. 
 
 All Patients attending dermatology outpatient department  and from 
Rheumatology department having SLE were randomly selected for the study. 
Minimum sample size was kept as 50 cases. The patients were interviewed in 
person. Written and informed consent of all patients were taken for the study. 
 
 Detailed case history of each patient with special attention to cutaneous 
lesions was taken. Gender, age, marital, obstetric and family history, history of 
autoimmune diseases, sunlight exposure, smoking, drugs and relapses was asked 
for. Specific details with regard to initial presentation of disease and history for 
involvement of other systems were asked. History of precipitating factors like sun 
exposure, infections, pregnancy and other relevant history was noted. 
  
Clinical features including: 
LE specific – malar rash, photosensitive dermatitis, maculopapular rash, SCLE, 
discoid rash; and 
 
LE nonspecific - alopecia, oral ulcers, raynauds phenomenon, hyperpigmentation, 
livedoreticularis, sclerodactaly, urticarial, facial edema, vasculitic ulcer, bullous 
SLE, nail fold infarct, chill bain, LE tumidus, EM/TEN presentations and others 
are noted following detailed clinical assessment. 
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Any systemic involvement was looked for and noted; and disease severity was 
correlated with cutaneous manifestations. 
 
Detailed dermatological examination with inclusion of histopathological finding 
by skin biopsy as well as dermascopic visualization was performed as and when 
required. 
 
Routine investigations of all patients were performed which included complete 
blood hemogram, ESR, liver and renal function tests. Urinalysis and sediments 
were looked for as well.  
 
Antinuclear antibody study was done in all patients. RF and anti dsDNA status 
was noted. 
 
Skin biopsy for histopathological examination was done in relevant cases. 
 
Chest X ray, mantou study, ultra sonogram, echocardiography as per needs to 
detect any associated systemic involvement was done. 
 
4.9 Follow up procedures/visits: 
 Patients were advised to come for review after 1 week . The reports of all 
the investigations were collected and recorded and classified. Patients were started 
on appropriate treatment for the skin lesions. 
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4.10 Statistical analysis: 
 The collected data were analysed with IBM.SPSS statistics software 23.0 
Version.To describe about the data descriptive statistics frequency analysis, 
percentage analysis were used for categorical variables 
 
4.11 Ethical issues: 
 Participants were made aware about the nature and purpose of the study. It 
was also informed to all the participants that all data provided by the patients will 
be kept confidential and will be used only for the study purpose. Willingness and 
signature of the participants were taken on a previously designed consent form. 
 
 Written consents were obtained from all the subjects who participated in 
the study before data are collected. Detailed description of the study and the 
aspects of patient confidentiality are explained to the subject and voluntary 
participation is sought. Institutional ethics committee of Madras medical college 
reviewed the study proposal for ethical consideration and approval of the 
committee was obtained prior to the study. 
 
  
Observations & Results 
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OBSERVATIONS 
 
AGE AND SEX INCIDENCE 
 
TABLE 1.A. AGE DISTRIBUTION 
AGE RANGE NUMBER OF CASES PERCENTAGE 
Upto 20 yrs 17 27 
21 - 30 yrs 29 47 
31 - 40 yrs 11 17 
Above 40 yrs 5 8 
Total 62 100 
 
 
COMMENTS 
 Out of the 62 patients , about 91%  of the patients were below 40 years of 
age. The prevalence is found to be highest in the the age group of 21 to 30 
years(47%).  
 The disease commonly manifested early in adult life.   
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1.B. GRAPHICAL REPRESENTATION OF AGE DISTRIBUTION 
 
 
TABLE 2.A. GENDER DISTRIBUTION 
SEX NUMBER OF CASES PERCENTAGE 
Female 54 87.1 
Male 8 12.9 
Total 62 100.0 
 
 
COMMENTS 
 Of the 62 patients, 54 (87.1%) were females and 8 (12.9%) were males. 
The prevalence of the disease is higher in the female population. The 
female to male ratio is 7:1 corroborating with studies worldwide. 
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2.B. PICTORIAL REPRESENTATION OF GENDER DISTRIBUTION 
 
 
TABLE 3.A. POSSIBLE TRIGGERS/ PRECIPITATING FACTORS 
POSSIBLE TRIGGERS NUMBER OF CASES PERCENTAGE 
DRUG 1 1.6 
INFECTION 4 6.5 
PHOTOSENSITIVITY 32 51.6 
PREGNANCY 7 11.3 
STRESS 1 1.6 
NIL 17 27.4 
TOTAL 62 100.0 
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COMMENTS 
 The probable precipitating or exacerbating factor was found in 88% of the 
patients out of which the majority, i.e. 32 patients (51.2%) had a history 
suggestive of photosensitivity as a probable triggering factor.  
 27.4% gave no history suggestive of any triggers.7 patients (11.3%) 
developed first symptoms / flare during pregnancy. 
 
3.B GRAPHICAL REPRESENTATION OF PROBABLE 
PRECIPITATING/EXACERBATING FACTORS  
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CLINICAL FEATURES 
 
4.1. PICTORIAL REPRESENTATION OF PATIENTS PRESENTING 
WITH SKIN LESIONS  
 
 
 
37 out of the 62 patients (60%) had skin lesions at the time of 
presentations. 88.7%, i.e, 55 patients had developed skin lesions at some point 
during the course of the disease. 
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TABLE 4.2.A. TABLE SHOWING PREVALANCE OF LE SPECIFIC 
LESIONS 
 
LE SPECIFIC LESION NUMBER OF CASES PERCENTAGE 
Lupus Profundus 1 2 
SCLE 2 3 
Discoid Lupus 11 18 
Gen maculopapular Rash 30 48 
Photosensitive Dermatitis 32 51 
Malar Rash 43 69 
 
COMMENT 
 Malar rash was the most common LE specific lesion observed and was 
seen in 43 patients (69%). It was followed by photosensitive dermatitis 
which was seen in 51% and generalized maculopapular rash seen in 48% of 
the study population. There were 11 patients (18%) with DLE lesions , 2 
with SCLE and 1 with Lupus profundus.  
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4.2.B. GRAPHICAL REPRESENTATION OF LE SPECIFIC LESIONS 
 
 
 
4.2. C PICTORIAL REPRESENTATION OF PATIENTS WITH MALAR 
RASH 
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COMMENT 
 Cutaneous erythema or darkening was seen in the sun exposed malar 
region associated with fine scaling and/or edema giving a typical butterfly 
rash over the cheek. Typical sparing of nasolabial folds is observed. 
 
4.2.E.  PICTORIAL REPRESENTATION OF GENERALISED 
MACULOPAPULAR RASH 
 
 
COMMENT 
 48% developed a diffuse, maculopapular erythema and fine scaling of face, 
upper trunk and extremities.  
 Malar rash , photosensitive dermatitis and generalized maculopapular rash 
were the common acute cutaneous LE lesions observed. 
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4.2.F. PICTORIAL REPRESENTATION OF DISOID RASH 
 
 
COMMENT 
 Discoid lupus was seen in 11 patients(18%). 2 patients developed scarring 
alopecia following DLE lesions over the scalp. 2 patients had mucosal 
DLE lesions over the lips and one case of disseminated DLE was noted. 
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TABLE 4.3.A. NONSPECIFIC LESIONS IN SLE 
LE NON SPECIFIC 
LESIONS 
NUMBER OF 
CASES PERCENTAGE 
NSDHL 46 74.2 
SHL 4 6.4 
ORAL ULCER 43 69.3 
PIGMENTATION 18 29 
NAIL CHANGES 12 19.3 
VASCULITIS 10 16.1 
RAYNAUDS PHENOMENON 9 14.5 
FACIAL EDEMA 8 12.9 
URTICARIA 6 9.6 
EMF 2 3.2 
LP-LE OVERLAP 1 1.6 
 
COMMENTS: 
 Non scarring diffuse hair loss was the most common nonspecific LE lesion, 
seen in 48 patients (77%). This was followed by oral ulcers, seen in 43 
patients; hyperpigmentation in 18 patients, nail changes in 12 patients, 
vasculitic changes in 10 patients; Raynauds phenomenon in 9 patients; 
facial edema in 8 patients; and urticaria in 6 patients.2 patients showed 
EMF lesions and one patient had LP-LE overlap. 
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4.3.B PICTORIAL REPRESENTATION OF  LE NON-SPECIFIC 
LESIONS 
 
 
4.3.C. PICTORIAL REPRESENTAION OF HAIR CHANGES
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COMMENTS: 
 Diffuse hair loss was the most common nonspecific LE lesion seen in 46 
out of the 62 patients. Non-scarring diffuse hair loss with lupus hair was 
present in five patients and non scarring alopecia along with scarring 
alopecia was seen in one patient. 4 patients showed scarring hair loss of 
which 2 cases were associated with scalp DLE. 
 
4.3.D.PIE CHART SHOWING ORAL MUCOSAL CHANGES. 
 
COMMENTS : 
 43 cases (69%) showed oral mucosal changes and it was the second most 
common non specific LE lesion seen. One patient developed associated 
nasal ulcers, and one patient showed genital ulcerations. Glossitis was 
present in one patient.  
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4.3.E. CHART SHOWING PREVALENCE OF DIFFUSE PIGMENTARY 
CHANGES 
 
 
COMMENTS: 
 Diffuse hyperpigmentation was seen in 18 patients. Patients with DLE 
developed post inflammatory hypopigmentation.  
 
4.3.F.CHART SHOWING PREVALENCE OF NAIL CHANGES 
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COMMENTS: 
 12 patients showed nail changes. Bluish discoloration of the nails and red 
lunula were seen in 6 and 2 patients respectively. Others showed nail 
ridging and one patient developed paronychia.  
 
SYSTEMIC INVOLVEMENT 
 4.4.A.TABLE SHOWING PREVALNCE OF SYSTEMIC 
INVOLVEMENT. 
 
SYSTEMIC INVOLVEMENT NUMBER OF CASES PERCENTAGE 
Constitutional symptoms 49 79 
Musculoskeletal 46 74 
Hematology 37 59.6 
Renal 30 48.3 
Nervous system 13 20.9 
GIT 12 19.3 
 
COMMENTS : 
 79% of patients developed constitutional symptoms of fever myalgia and 
fatigue. The most common system affected was the musculoskeletal system 
(74%) , followed by hematological involvement (59.6%) , renal 
involvement (48.4%) , cardovascular involvement (25.8%), neurological 
involvement (20.9%) and GIT involvement (19.3%). 
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4.4.B. PICTORIAL REPRESENTATION OF SYSTEM INVOLVEMENT. 
 
 
4.4.C. CHART SHOWING PREVALENCE OF MUSCULOSKELETAL 
INVOLVEMENT. 
 
 
COMMENTS : 
 This is the most common system involved, with 79% prevalence among the 
study group. Most patients presented with polyarthritis, myalgia, arthralgia. 
Dactilitis was seen in 2 patients and osteonecrosis in one. 
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4.4.D CHART SHOWING PREVALENCE OF RENAL INVOLVEMENT. 
 
 
COMMENTS: 
 Renal involvement was seen in 48.4% of the study group. It was also 
associated with higher morbidity. Urine analysis revealed proteinuria in 20 
patients (32.3%), and renal biopsy confirmed a diagnosis of Lupus 
nephritis in 26 patients (86.6%). 
 
 All patients were ANA-positive (100%) and anti ds-DNA was detected in 
42 patients (67.7%). 19 patients with anti ds-DNA antibodies had evidence of 
lupus nephritis. 
  
Clinical images 
  
 CLINICAL IMAGES 
 
 
IMAGE 1. BLUISH DISCOLORATION OF NAILS. 
  
IMAGE2. ACLE IMAGE 3 SCALP DLE 
 
  
   
    
 
IMAGE 4. DISSEMINATED DISCOID LUPUS ERYTHEMATOSIS 
  
  
IMAGE 5 VASCULITIC LEG ULCER. 
 
  
IMAGE6 CUTANEOUS VASCULITIS 
 
   
  
  
 
IMAGE 7 NON SCARRING DIFFUSE HAIR LOSS,  
WITH LUPUS HAIR 
 
 
 
IMAGE 8 SCARRING HAIR LOSS 
  
                                   
 
 
 
 
 
IMAGE9 MALAR RASH WITH SPARRING OF NASOLABIAL FOLDS 
  
  
          
 
 
 
IMAGE 10 ORAL ULCERATION. 
 
  
IMAGE11 GENERALISD MACULOPAPULAR RASH 
 
       
  
IMAGE 12 PSORIASIFORM SCLE LESIONS 
                               
  
                                     
 
 
IMAGE 13 HLE section in a  case with acle showing flaky hyperkeratosis, 
parakeratosis, kerotitc plugging, mild acanthosis, spongiosis, basal layer 
degeneration, few colloid bodies. Plenty of inflammatory infifltrate in 
papillary dermis consisting of lymphocytes and histiocytes,mainly around 
blood vessels. Few areas of nuclear dust seen. 
Discussion 
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DISCUSSION 
 
 In this study, the age of the patients ranged from 12-57 years. The peak age 
of onset was between the second and third decade, which is lesser when compared 
to the peak age of onset observed in the western world, that being the third and 
fourth decade. Study by Kole,90 et al noted the median age of onset as twenty-five 
years. Our study showed one case of late onset SLE (defined by onset >50 years).  
 
 The female to male ratio was 7:1, which was similar to the ratio recorded 
in western literature. It was less when compared to the Indian study by Alakes 
Kumar Kole and Ghosh, in Institute of PGMER, Kolkata with 150 patients, which 
showed a higher ratio of 14:1.90 Our study had 4 males, all of whom had severe 
systemic involvement, as observed in literature. 
 
 In this study, photosensitivity was present in 32 patients (51.6%); and is 
considered to be the probable precipitating/exacerbating factor. This correlates 
with the incidence of 60% as given in literature.  
 
 17 (27.4%) patients had no obvious triggering factor. In 11 patients, 
pregnancy caused SLE flares, and two patients developed preeclampsia. 15 
(24.2%) women in the reproductive age group had one or more abortions. 
 
 4 patients (6.75%) gave history of preceding infections, which included 
dengue and upper respiratory tract infections. 
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 1 case of drug induced SLE was noted (carbamazepine). 
 
 60% of the patients presented with acute cutaneous lupus lesions. Malar 
rash occurred in 69% which comparable to findings in literature. A higher 
percentage of 80% was noted in the study by Kole, et al; but is comparable to a 
study by Vadya, et al in western India (53.18%). 
 
 DLE lesions were seen in 18%, which is corroborated with the 20% seen in 
the Kole et al study, and 20-15% seen in western literature. 
 
 Diffuse macular popular rash was seen in 48%, which was much higher 
when compared with the study of Kole, et al with 26.6%. 
 
 Lesions of SCLE were detected in 3% and 1 case of Lupus profundus was 
observed. 
 
 TEN variant of SLE, bullous lupus, chilblain lupus were not seen in during 
the course of this study. 
 
 Among LE nonspecific lesions,  non scarring diffuse hair loss was the most 
common lesion seen (74.2%), similar to 84.67% noted by Kole, et al and *@% by 
Malavya, et al. 
 
 The incidence of oral ulcers was 69.3%, which was higher than the 56.67% 
noted by Kole,et al and the 20% seen in western literature. 
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 Raynaud’s phenomenon was present in 14.5%. 19.3% of patients showed 
nail changes and 6 patients showed bluish discoloration of nails of which one 
patient had a history of Raynaud phenomenon and one a history of digital ulcer. 
 
 Vasculitic ulcer was seen in 16.1 %, which included leucocytoclastic 
vasculitis and two patients with leg ulcers. 
 
 6 patients developed urticarial lesions, and 18 patients had diffuse 
hyperpigmentation. 2 cases of EMF, 1 case of LP-LE overlap were observed.  
 
 Other systemic involvement included constitutional symptoms (79%) of 
fever, malaise, fatigue. Musculoskeletal system was most commonly involved 
(74%) presenting with polyarthritis, arthralgia, myalgia, and 2 cases of dactilitis 
and a single case of osteonecrosis. 
 
 Renal involvement was seen in 48.4% of the study group. It was also 
associated with higher morbidity. Urine analysis revealed proteinuria in 20 
patients (32.3%), and renal biopsy confirmed a diagnosis of Lupus nephritis in 26 
patients (86.6%). 
 
 Anemia was the most common hematological manifestation (59.6%) noted, 
followed by thrombocytopenia. 
 
 Neurological manifestations seen included seizures seen in 6 patients. 
Psychosis was seen in one patient and a single case of multicentric infarcts was 
also noted. 
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 Cardiovascular system involvement such as Mitral Regurgitation, Mitral 
valve Prolapse were seen in 2 patients and pericardial effusion in one patient. 
 
 GIT manifestations such as hepatomegaly with fatty liver was seen in one 
patient, esophagitis in two patients, and ascites in one. 
 
 In this study LE non specific lesions, such as diffuse non scarring hair loss 
and generalized macular popular rash was associated with more active disease. 
  
Conclusion 
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CONCLUSION 
 
 The commonest age group to be affected was observed to be second and 
third decade. Female preponderance was seen with a  female to male ratio of 7:1. 
Multiple precipitating factors are involved in the clinical manifestation of disease. 
 
 Photosensitivity was the commonest among the precipitating factors, 
followed by pregnancy, infection/stress. Fever, easy fatigability, diffuse  hair loss, 
and arthralgia were the common symptoms seen. Malar rash was the commonest 
disease specific lesion, followed by photosensitive dermatitis and generalized 
macular popular rash. Diffuse hair loss was virtually present in all patients and 
was the commonest non specific but disease related skin lesion.  Generalized 
macular papular rash was associated with active disease. 
 
 Musculoskeletal system was the   commonest system involved, followed 
by renal and central nervous system involvement. Renal involvement was 
associated with the most morbidity. 
 
 Antinuclear antibodies were positive in all patients in this study.67.7% 
were positive for anti ds-DNA antibodies and  19 patients (45.2%) with anti ds-
DNA antibodies had evidence of lupus nephritis. 
 
 Cutaneous manifestations in SLE can yield valuable diagnostic as well as 
prognostic information. As skin lesions are associated with increased morbidity, 
proper understanding of cutaneous manifestations is necessary for early diagnosis 
and effective intervention in patients with SLE. 
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Drugs 
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DERMATOLOGICAL EXAMINATION 
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Malar Rash       Discoid rash 
 
Photosensitive dermatitis     Lupus Profundus 
 
Generalised MP Rash 
 
SCLE 
 
 
Le-Non specific 
 
Alopecia       Mucosal / Lichenoid discoid 
Lupus 
 
Oral Ulcer       Chill Bain 
 
Raynaud’s ph       LE Tumidus 
 
Sclerodactaly       DLE / LE overlap 
 
Linedo  Reticularis      Hyperpigmentation 
 
Vasculitic Ulcer / Bullous / PG / EM / TEN   Nail field and infarct 
Systemic 
 
  
 
Constitutional Symptoms      Renal 
 
LNE / HSM        Pulmonary 
 
Arthritis 
 
Neurological Status 
 
Cardiac Status 
 
 
Lab Investigations 
 
CBC         CXR 
 
ESR         USG 
 
Urine Analysis       ECG, Echo 
 
Skin Biopsy HPE 
 
ANA 
 
Anti ds DNA 
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 The purpose of this study is to analyse the various patterns of cutaneous 
manifestations in SLE and its association with systemic disease. 
 
Study Design  :  Cross sectional Observational Study 
 
Study Procedures :  
 In this study  detailed history of patient will be taken, followed by detailed 
dermatological examination. Histopathological examination by skin biopsy if required 
will be done. Blood hemogram, ESR, urine analysis.  Liver and renal function tests. 
Chest X ray, ultrasonogram, echocardiography as per needs to detect any associated 
systemic involvement. Treatment for the skin lesions will be give accordingly with 
advice on sun protection will be given. 
 
Possible Risks : No risks to the patient 
 
Possible benefits  
To patient : Complete dermatological work up with proper treatment and advice on 
prevention of skin lesions. 
 
To doctor & to other people :  The results of the study will help in the understanding of 
the cutaneous manifestations of SLE which can indicate disease activity and is essential 
for most efficient management. 
 
Confidentiality of the information obtained from you : The privacy of the patients in 
the research will be maintained throughout the study. In the event of any publication or 
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DURATION 
IN YEARS
POSSIBLE
TRIGGERS 
PRESENTING 
SYMPTOMS
PRESN 
SKIN
CONS 
TITUT
EDEMA MSK
RAY 
PH
PIGME
NTATI
ON
MPR HEMAT
NERV 
OUSY
GIT RENAL
CARDIO 
PUL
VASULITI
C ULCERS
URTICA
RIA
MALAR 
RASH
DISCOID 
RASH
ORAL 
ULCERS
ALOPECIA NAILS SKIN LESIONS
SYSTEMIC 
INVOLVEMENT
LABORATORY FINDINGS ANA dsDNA
ane
mia
PROTEIN
URIA
1 38 F N N 0.5 INF
Fever , B/L pedal 
edema,↓urine 
output,breathlessn
ess
Y Y N Y Y Y Y nil nil nil NSDHL nil
ICH,Hyperpigmenta
tion B/L LL & UL
Lupus nephritis IV, 
HTN, Hypothyroid
ANA+, low C3, Sr.Cr - 
1.5, Hb -9, renal biopsy
Y Y Y
2 32 F Y N 0.58 PREG polyarthritis N N Y Y nil nil nil NSDHL nil
Pigmentation oral 
cavity
musculoskeletal 
invol
ANA POSITIVE Y
3 40 F Y N 3 PS
polyarthritis, 
mucocutn
y N N Y Y Y Y present nil present NSDHL nil PIH UL, face
musculoskeletal 
invol,hemat
Hb-9, ANA positive Y     Y
4 13 F 1.5 PS
fever, 
polyarthritis,hair 
loss, mucocutn
y Y N Y Y Y Y present nil present NSDHL nil PIH face, limbs
musculoskeletal 
invo, hemat
hb-9, ANA positive, skin 
biopsy
Y Y
5 34 F Y Y 4 PREG
stress fracture, 
knee 
osteonecrosis, low 
grade multifocal 
OM
Y N Y Y nil nil nil nil nil photosensitivity
musculoskeletal 
invo, b/l papillitis
ANA positive, anti Sm+, 
U1RNP+, dsDNA+, 
↑ESR, ↑CRP
Y Y
6 16 F 0.5 nil
MP rash, fever, 
polyarthralgia
y Y N Y nil nil present NSDHL nil tinea versicolor
musculoskeletal 
invol
ANA positive Y
7 18 F 0.5 PS
fever, proximal 
muscle weakness
Y N Y Y Y Y nil nil present NSDHL nil MP rash face , trunk
dengue IgM+, 
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anemia of chronic 
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Hb 9.4, leukopenia, 
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DCT+,↑CRP, skin biopsy, 
Y Y Y
8 16 F 6 nil
dysphagia, loss of 
weight, 
polyarthralgia
N N Y Y Y Y present nil present NSDHL nil
tinea corporis, PIH 
UL
sjogren synd DCT+, Hb-6.5 Y
9 21 F N 0.5 PS
fever, mucocutn -
black nose, 
polyarthralgia, 
pedal edema
y Y Y Y Y Y Y present nil present NSDHL nil urticaria anemia, AIHA Hb- 6.5, DCT+ Y
10 42 F Y N 5 PS
fever, oral ulcers- 
mucocutn
y Y N N Y Y present nil present nil nil
photosensitve 
dermatitis, chelitis
hypothyroid, 
pulmonary
Ct chest - lower lobe 
atelectais
11 32 F N Y 5 PREG
mucocutn flare, 
pedal edema 
y Y Y N Y present nil present nil nil MP rash, LNE Lupus nephritis IV dsDNA+, ↑ESR, low C3 Y
12 30 F N Y 2 PREG
fever, pedal 
edema, 
polyarthritis
Y Y Y Y Y Y Y present nil nil NSDHL present
photosensitive rash, 
chronic urticaria, 
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hemat, anemia of 
chronic disease
Hb-8, ANA+ Y Y
13 23 F N 5 nil
menorrhagia, 
malar rash
y N N N Y Y Y Y Y present nil present NSDHL nil
photosensitive rash, 
chronic urticaria, 
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lupus nephritis V
thrombocytopenia, 
proteinuria 3+,ANA 
speckled+, Sm+,dsDNA 
nucleosomal+, RNP+, 
low C3,C4, lupus 
coagulation test+
Y Y Y
14 30 F Y N 2 nil polyarthritis N N Y Y Y Y nil nil present nil nil
raynauds 
phenomenon, 
dactylitis
pulmonary ILD, pul 
TB GIT- dilated 
oesophagus, 
?overlap
dsDNA+, ↑ESR, low C3, 
C4
Y
15 35 F Y N 6 PS
fever, alopecia, 
pedal edema
y Y Y N Y Y nil nil nil NSDHL present
raynauds ph, 
burning of P & S
polyarthritis, 
myalagia, 
osteoporosis
ANA positive, BMD 
suggestive of 
osteoporsis
Y
16 27 F N N 2.5 PS
fever, 
Maculopapular 
rash, joint pain
y Y N Y Y Y present nil present NSDHL present
raynauds ph, facial 
skin tightening
musculoskeletal 
sys inv
ANA positive, 
thrombocytopenia
Y
17 27 F N N 14 nil
bleeding gums, 
intacerebral 
hrmge, hemeturia, 
ITP
Y N N Y Y Y Y present nil present NSDHL nil
post inflamatory 
hyperpigmentation
Tuberculosis, 
arthralgia, hemat, 
lupus nephritis 
stage IV  
anemia, Sm+, dsDNA+, 
low C3, C4, proteinuria
Y Y Y
18 34 F Y N 8 PS
malar rash, 
arthritis, fever
y Y N Y Y Y present nil nil nil nil
photosensitive 
dermatis
musculoskeletal 
invol, hemat
anemia, ↑ESR, ANA + Y Y Y
19 12 M 1 PS fever, malar rash y Y N N Y Y Y present nil present nil present
photosensitive 
dermatitis, PIH 
generalised 
LNE cervical, 
hepatomegaly, 
grade III fatty liver
anemia, 
thrombocytopenia, 
ANA+
Y Y
MASTER CHART
20 26 F Y N 6 PS
malar rash, 
arthritis
y Y N Y Y Y present nil nil NSDHL present
photosensitive 
dermatitis, MP rash 
with 
hyperpigmentation
musculoskeletal 
invol
ANA positive Y
21 20 F 2 nil
facial edema, 
dactylitis
y N Y Y Y Y present nil present NSDHL nil raynauds ph
musculoskeletal 
invol, 
hypothyroidism
thrombocytopenia, 
ANA+, anti thyroid 
antibody +
Y
22 29 M 5 nil joint pain N N Y Y Y Y Y nil present present SHL nil
SCLE, vasculitic 
ulcer, genrl 
hyperpigmentation
lupus nephritis V, 
hypokalemic 
periodic paralysis, 
hemat
ANA positive, renal 
biopsy
Y
23 42 F Y N 11 PS
loss of weight, 
fever, joint pain
Y N Y Y Y Y present nil present NSDHL nil
vasculitic ulcer, 
hyperpigmentation
musculoskeletal 
invol
anti dsDNA positive Y
24 30 F Y N 0.58 PS
pedal edema, dec 
urine output, poly 
arthralgia, fever, 
fatigue, fits
Y Y Y Y Y Y Y Y Y nil nil nil NSDHL nil
hyperpigmentation 
legs , xerosis, ulcer 
foot
musculoskelet 
invol, renal , cns, 
RS- TB effusion
↑ESR, ANA+, dsDNA +, 
renal bx
Y Y
25 44 F Y N 0.5 PS
fever, polyarthritis, 
dyspnoea, syncope
Y N Y Y Y Y Y present nil present NSDHL nil
oral cavity 
pigmentation
musculoskeletal 
invol
↑ESR, ANA+ Y
26 65 F Y N 0.08 nil
polyarthritis, fever, 
facial edema
Y Y Y Y Y Y present nil nil NSDHL nil nil
renal invol, CVS- 
MR, musculoskel 
invol
↑ESR, echo- MR, ANA+, 
↓creaƟnine clearance, 
proteinuria
Y Y Y
27 33 F Y Y 3 PS
poly arthritis, hair 
loss, fever, fatigue
y Y N Y Y Y present nil present NSDHL nil
photosensitive 
dermatitis
musculoskeletal 
invol, lupus 
nephritis IV
anemia, ↑ESR, ANA +, 
dsDNA+, low C3, C4, 
renal bx
Y Y
28 18 F 0.5 nil
polyarthritis, 
fever,hair loss
y Y N Y Y present nil nil NSDHL nil nil
musculoskeletal 
invol, renal
↑ESR, ANA+, dsDna+, 
proteinuria, casts+
Y Y Y
29 23 M 10 PS
polyarthritis, pedal 
edema, dyspnoea, 
fever, hairloss
y N Y Y Y Y Y Y nil nil present NSDHL present
raynauds ph, 
urticaria
renal, musculosk 
invol, CVS- MVP+
↑ESR, ANA+, 
proteinuria, ↓creat 
clear, echo - MVP
Y Y
30 26 F Y N 3 nil
polyarthritis, pedl 
edema, raynauds, 
gangrene toes, 
fever, fatigue
Y Y Y Y Y nil nil present NSDHL nil
raynaud ph, herpes 
zoster
lupus nephritis III, 
musculoskeletal 
invol
↑ESR, ANA+, dsDna+, 
proteinuria, casts+
Y Y Y
31 14 F 0.17 PS
fever,fatigue, fits, 
polyarthritis, 
migraine, 
hemiplegia
Y N Y Y Y present nil present NSDHL nil nil
CNS- CVT 
multicentric 
infarcts
anemia,↑ESR, 
ANA+,dsDNA+, ACL
Y Y Y
32 16 F 0.17 PS
fever, oral ulcers, 
ACLE
y Y N N Y Y present nil present NSDHL nil
photosensitive 
dermatitis
RS- pneumonia, 
pleural effusion
anemia, ↑ESR, CXR- 
basal pneum, pl eff, 
ANA+, dsDNA+
Y Y Y
33 30 F Y 3 PS
polyarthritis, ACLE, 
hair loss, 
dysphagia, 
raynauds ph
y N N Y Y Y Y Y Y present present present NSDHL nil
photosensitive 
dermatitis, DLE, ul 
leg, finger tip scar
lupus nephritis, 
GIT- oesophagitis, 
hepatomegaly, 
musculosk inv
anemia, 
thrombocytemia, ↑ESR, 
proteinuria, ANA+, renal 
bx
Y Y Y
34 18 F 0.17 STRESS
fever, 
ACLE,polyarthritis, 
constipation, 
malena, fits
y Y N Y Y Y Y Y Y present nil nil NSDHL nil
eczema, tinea pedis 
&cruris
musculoskel inv, 
CNS, GIT, CVS- MR, 
MVP
anemia, ↑ESR, echo- 
MR, MVP, ANA+, CT 
brain abn, UGI scopy
Y Y
35 21 F 0.25 nil
fits, polyarthritis, 
hair loss, pedal 
edema, fever
y Y Y Y Y Y present nil nil NSDHL nil nil
CNS, lupus 
nephritis IV, 
musculosk invol
proteinuria, ANA+, 
↓creat clear, EEG abn, 
renal bx
Y Y
36 25 F 1 nil
polyarthritis, fever, 
myalgia, facial 
edema, 
oligomennorrhea, 
MN goitre
Y Y Y Y Y nil nil present NSDHL nil ichthyosis legs
musculosk invol, 
lupus nephritis, 
MN goiter
anemia, ↑ESR, ANA+ Y Y
37 27 F N Y 10 INF
polyarthritis, fits, 
hair loss, fever, 
facial edema
y Y Y Y Y Y present present present NSDHL present arachinodatly
musculoskel invol, 
CNS
anemia, ↑ESR, CRP+, 
ANA+
Y Y
38 28 M N Y 1 INF
fever, facial edma, 
pedal edema, 
insomnia, 
polyarthritis, visual 
abn
Y Y Y Y Y Y Y present  nil present NSDHL nil
tinea cruris, scrotal 
eczema
musculoskl 
inv,lupus nephrtis 
III, Cardiomegaly, 
pericardial 
effusion, retinal 
hrge, 
hepatomegaly
aplastic anemia, 
leukopenia, echo, ANA+, 
dsDNA+, 
hypocomplementamia, 
renal biopsy
Y Y Y
39 32 M N Y 4 PS
fever, polyarthritis, 
hair loss, raynaud, 
gangrene, burning 
feet
y Y N Y Y Y Y Y nil nil present NSDHL present
multiple palpable 
purpuric lesions 
legs, raynauds, 
vasculitis
musculoskl invol, 
hemat, vasculitis, 
gangrene, lupus 
nephritis IV
↑ESR, ANA+, dsDNA+ 
bld urea↑, low creat 
clear, renal biopsy
Y Y
40 17 F 0.17 nil
vomiting, fever,fits, 
plyarthritis, ACLE, 
loss of weight
y Y N Y Y Y Y present nil present NSDHL nil oral candidiasis
musculoskl, CNS, 
eye- blepheritis, 
conjunctivitis
↑ESR, anemia, ANA+, 
dsDNA+
Y Y Y
41 26 F Y Y 0.08 PS
fever, polyarthritis, 
vomiting
Y N Y Y Y Y nil present present SHL nil
erythema 
multiforme 
musculoskeletal 
invol
anemia, ↑ESR, ANA+, 
dsDNA+,skin biopsy
Y Y Y
42 30 F Y Y 1 PS
oral, nasal, genital 
ulcer, hair loss, PA, 
dyspnea, chestpain
y N N N Y Y present present nil NSDHL nil
target lesions, 
paronychia
musculoskeletal 
invol, 
cardiomegaly
ANA+, dsDNA+, skin 
biopsy
Y Y
43 22 F 3 PS
fever, depression, 
hair loss
y Y N N Y Y Y Y present nil present NSDHL nil oral thrush, scabies
musculoskl invl, 
CNS- psychosis, 
CVS- MR/AR
anemia, ↑ESR, echo, 
proteinuria, casts, low 
creat clear
Y Y Y
44 30 F N Y 0.5 PS
fever,hair loss, 
ACLE, oral, genital 
ulcer
y Y N N Y Y present present present NSDHL present
genital erosions, 
ichthyosis
RS- bronchitis, 
lupus nephritis IV
anemia, ↑ESR, 
thrombocytopenia, 
ANA+,renal biopsy
Y Y
45 24 F 1 nil
fever, bleeding 
gums,menorrhagia, 
fits, facial edema
Y Y N Y Y Y nil nil nil NSDHL present nil
musculoskl invl, 
CNS, lupus 
nephritisIV
pancytopenia, anemia, 
↑ESR, ANA+, dsDNA+, 
renal bx
Y Y
46 26 F N Y 0.5 PREG
fever, hair loss, 
polyarthritis, 
oligomenorrhea, 
lymphadenitis
y Y N N Y Y Y present present present NSDHL nil
scabies, vasculitic 
ulcers, submental 
lymphadenitis
musculoskl invl, 
lupus nephritis V
anemia,↑ESR, 
thrombocytopenia, 
PT&PTT ↓, ↓C3,C4, 
ANA+, dsDNA+, renal 
biopsy
Y Y Y
47 36 F Y N 4 PS
fever, polyarthritis, 
oral ulcer, fits, 
amenorrhea
Y N Y Y Y nil present present SHL nil DLE , scabies
musculoskl invl, 
CNS
anemia, ↑ESR, ANA+, 
dsDNA+
Y Y Y
48 20 M 0.17 nil
fever, polyarthritis, 
pedal edema, facial 
edema, ulcer foot, 
vomiting
Y Y Y Y Y Y nil nil nil nil nil vasculitic ulcer foot
musculoskeletal 
invl, lupus 
nephritis III, GIT- 
ascitis
anemia, ↑ESR, 
proteinuria, ANA+, 
dsDNA+, RF+, usg abd, 
renal bx
Y Y Y Y
49 17 F 0.17 nil
fever, headache, 
vomiting, 
polyarthritis
Y N Y Y Y Y present nil nil NSDHL nil
pityriasis versicolor, 
pediculosis capitis
musculoskl invl, 
lupus nephritis IV, 
CNS, 
hepatomegaly
↑ESR, usg abd, 
proteinuria, low creat 
clear,ANA+,renal biopsy
Y Y
50 10 M 0.08 PS
fever, malar rash, 
joint pain
y Y N Y Y Y Y present nil nil NSDHL nil PIH
RS- basal 
pneumonia, 
musculoskl invl, 
gen LNE
leukocytosis, ↑ESR, 
thrombocytopenia, CXR, 
ANA+, dsDNA+
Y Y
51 25 F 0.08 PS
fever, hair loss, 
malar rash
y Y N N Y Y Y present nil present NSDHL nil
photosensitive 
dermatitis
lupus nephritis III, 
gen LNE
anemia,↑ESR, 
proteinuria, casts +, 
ANA+, dsDNA+, renal 
biopsy
Y Y Y Y
52 24 F 0.17 PS
fever, hair loss, 
malar rash, joint 
pain, fits, pedal 
edema
y Y Y Y Y Y Y Y present nil present NSDHL nil seb derm
musculoskl invl, 
lupus nephritis V, 
CNS
anemia, 
↑ESR,lekocytopenia, 
proteinuria, cast +, ↑bld 
urea, s. creat, low creat 
clear, ANA+, dsDNA+, 
renal bx 
Y Y Y Y
53 25 F N Y 0.4 PS
fever, malar rash, 
polyarthritis, pedal 
edema
y Y Y Y Y Y Y Y present nil present NSDHL nil
photosensitive 
dermatitis, PIH 
generalised 
musculoskl invl, 
lupus nephritis III
anemia, ↑ESR, 
proteinuria, cast+, ↑bld 
urea, ↑s.creat, low creat 
clear, ANA+, dsDNA+, 
renal bx
Y Y Y Y
54 32 F N Y 2 PREG
joint pain, 
dyspnoea, facial 
edema
N Y Y Y Y Y Y Y present nil nil NSDHL nil
photosensitivity, 
PIH
mskl invol, hemat, 
pericardial 
effusion, renal -LN
ANA+, dsDNA+, low 
C3,C4
Y Y
55 27 F N N 2 PS
fever, joint pain, 
MP rash
y Y N Y Y Y Y Y present present present SHL present urticaria mskl invol, hemat
ANA+, anemia, 
proteinuria
Y Y Y
56 57 F Y N 5 PS
DLE, oral ulcers, 
fever, joint pain
y Y N Y Y Y Y present present present nil present
disseminated dle, 
MP rash
mskl invol, hemat
ANA+, anemia, ↑ESR, 
PROTEINURIA
Y Y Y
57 23 F 7 nil joint pain N N Y Y Y nil nil nil nil nil hyperpigmentation
renal, musculosk 
invol
ANA-, dsDNA-, renal 
biopsy 
immunofluresence- full 
house effect
58 30 F Y N 1 INF
MP rash, fever, 
polyarthralgia,oral 
ulcer
y Y N Y Y Y present nil present nil nil
photosensitive 
dermatitis, 
hyperpigmentation, 
LICHENPLANUS, LP 
LE overlap
muscl invol
ANA+,dsDNA+, 
proteinuria, anemia
Y Y Y Y
59 12 M 2 PS MP rash y N N N Y Y Y Y present nil present nil nil SCLE mucocutn invol
ANA+, dsDNA+, 
proteinuria,anemia
Y Y Y Y
60 16 F 0.08 DRUG
TEN like rash, 
fever,oral ulcers
y Y N N Y Y Y present nil present nil nil TEN LIKE RASH
CNS- epilesy, 
Lymphadenitis
ANA+, elevated liver 
enzymes
Y
61 17 F 3 PS
MP rash, fever, 
joint pain oral 
ulcers
Y Y Y Y Y present nil present NSDHL nil EMF
musclsk invol, 
renal
ANA+, anemia, dsDNA+, 
proteinuria
Y Y Y Y
62 27 F Y Y 4 PREG
DLE, oral ulcers, 
fever, joint pain
y Y N Y Y Y Y Y nil present present NSDHL nil disseminated dle
muskl invol, renal, 
hemat
ANA+, dsDNA, anemia, 
proteinuria, skin biopsy, 
renal biopsy
Y Y Y Y
KEY FOR MASTER CHART 
 
F   - Female 
M   - Male 
Y   - Yes 
N   - No 
CHIL   - Children 
CONSTITUT - Constitutional Symptoms 
MSK   -  Musculoskeletal System 
RAY PH  - Raynauds Phenomenon 
MPR   - Maculopapular Rash 
HEMAT  - Hematology 
INF   - Infection 
PREG   - Pregnancy 
PS   - Photosensitivity 
NSDHL  - Non Scarring Diffuse Hair Loss 
SHL   - Scarring Hair Loss 
SCLE   - Subacute Cutaneous LE 
EMF   - Erythema Multiforme 
ANA   - Antinuclear Antibodies 
